THE yeast, *Saccharomyces cerevisiae*, has emerged as a powerful model system for the elucidation of the metabolism, cell biology, and regulation of eukaryotic lipids. Due to the strong homology of yeast proteins, pathways, and regulatory networks with those in higher eukaryotes, yeast has provided numerous insights into the genetics and biochemistry of lipid-related diseases. As a system for the study of eukaryotic lipid metabolism, the advantages of yeast include its vast, well-curated, and electronically accessible archives of genetic data, including those detailing gene--enzyme relationships in the pathways for lipid synthesis and turnover. Another major advantage is the rapidly increasing understanding of the regulation and localization of enzymes and the movement of lipids within and among cellular membranes and compartments in yeast.

This article presents an overview of progress in elucidating gene--enzyme relationships, cellular localization, and regulatory mechanisms governing glycerolipid metabolism in yeast. The metabolism covered in this YeastBook chapter includes the regulation, synthesis, and turnover of phospholipids and triacylglycerol (TAG) and their precursors in the context of changing growth conditions and nutrient availability. All glycerophospholipids in yeast, including the major phospholipids, phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidylcholine (PC), are derived from the precursor lipid, phosphatidic acid (PA) ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). A major topic of this review article is the tremendous recent progress in elucidating the complex regulatory mechanisms that control the connected and coordinated pathways involved in the synthesis of glycerophospholipids and TAG, which is also derived from PA ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}). The regulation of glycerolipid metabolism occurs at many levels and is a major topic discussed in this article. Adding complexity to analysis of the regulatory networks connected to lipid metabolism is the fact that critical signals controlling this regulation arise during the ongoing biosynthesis and turnover of the lipids themselves and involve precursors and metabolites embedded in the metabolism.

![Phospholipid structures. The diagram shows the structures of the phospholipid PA and the major phospholipids PI, PS, PE, and PC that are derived from PA. The hydrophilic head groups (*H*, *inositol*, *serine*, *ethanolamine*, *and choline*) that are attached to the basic phospholipid structure are shown in red. The four most abundant fatty acids esterified to the glycerol-3-phosphate backbone of the phospholipids are palmitic acid, palmitoleic acid, steric acid, and oleic acid. The type and position of the fatty acyl moieties in the phospholipids are arbitrarily drawn. The relative amounts of the phospholipids as well as their fatty acyl compositions vary depending on strain (*e.g.*, mutation) and growth condition.](317fig1){#fig1}

![Pathways for the synthesis of glycerolipids and their subcellular localization. Phospholipids and TAG share DAG and PA as common precursors. In the *de novo* synthesis of phospholipids, PA serves as the immediate precursor of CDP-DAG, precursor to PI, PG, and PS. PS is decarboxylated to form PE, which undergoes three sequential methylations resulting in PC. PA also serves as a precursor for PGP, PG, and ultimately CL, which undergoes acyl-chain remodeling to the mature lipid. Alternatively, PA is dephosphorylated, producing DAG, which serves as the precursor of PE and PC in the Kennedy pathway. DAG also serves as the precursor for TAG and can be phosphorylated, regenerating PA. The names of the enzymes that are discussed in detail in this YeastBook chapter are shown adjacent to the arrows of the metabolic conversions in which they are involved and the gene--enzyme relationships are shown in [Tables 1](#t1){ref-type="table"}--[3](#t3){ref-type="table"}. Lipids and intermediates are boxed, with the most abundant lipid classes boxed in boldface type. Enzyme names are indicated in boldface type. The abbreviations used are: TAG, triacylglycerols; PI, phosphatidylinositol; PA, phosphatidic acid; CDP-DAG, CDP-diacylglycerol; DAG, diacylglycerol; MAG, monoacylglycerol; Gro, glycerol; DHAP, dihydroxyacetone phosphate, PS, phosphatidylserine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PGP phosphatidylglycerol phosphate; CL\* precursor cardiolipin; MLCL, monolyso-cardiolipin; CL, mature cardiolipin; PMME, phosphatidylmonomethylethanolamine; PDME, phosphatidyl-dimethylethanolamine; PC, phosphatidylcholine; FFA, free fatty acids; Cho, choline, Etn, ethanolamine, Ins, inositol; Cho-P, choline phosphate; CDP-Cho, CDP-choline; Etn-P, ethanolamine phosphate; CDP-Etn, CDP-ethanolamine; PI 3-P, phosphatidylinositol 3-phosphate; PI 4-P, phosphatidylinositol 4-phosphate; PI 4,5-P~2~, phosphatidylinositol 4,5-bisphosphate; PI 3,5-P~2~, phosphatidylinositol 3,5-bisphosphate. Nucl, nucleus; ER, endoplasmic reticulum; Mito, mitochondria; LD, lipid droplets; G/E/V, Golgi, endosomes, vacuole; Pex, peroxisomes; Cyt, cytoplasma; PM, plasma membrane. CL\* indicates a precursor of cardiolipin (CL) with saturated acyl-chain that undergoes deacylation/reacylation to mature CL. See text for details.](317fig2){#fig2}

![Model for PA-mediated regulation of phospholipid synthesis genes. (A) Growth conditions (*e.g.*, exponential phase, inositol depletion, or zinc supplementation) under which the levels of PA are relatively high, the Opi1 repressor is tethered to the nuclear/ER membrane, and UAS~INO~-containing genes are maximally expressed (boldface arrow) by the Ino2-Ino4 activator complex. (Inset) Localization of Opi1, fused with GFP at its C-terminal end and integrated into the chromosome, being expressed under its own promoter in live cells growing logarithmically in synthetic complete medium lacking inositol (−Ins) and analyzed by fluorescence microscopy. (B) Growth conditions (*e.g.*, stationary phase, inositol supplementation, or zinc depletion) under which the levels of PA are reduced, Opi1 dissociates from the nuclear/ER membrane, and enters into the nucleus where it binds to Ino2 and attenuates (thin arrow) transcriptional activation by the Ino2--Ino4 complex. (Inset) Localization of Opi1, as described in A, except that the cells are growing logarithmically in medium containing 75 μM inositol. PA level decreases by the stimulation of PI synthesis in response to inositol (Ins) supplementation and by Zap1-mediated induction of *PIS1*, that results in an increase in PI synthesis in response to zinc depletion. The regulation in response to zinc depletion and stationary phase occurs without inositol supplementation. Pah1 and Dgk1 play important roles in controlling PA content and transcriptional regulation of UAS~INO~-containing genes. The synthesis of TAG (which is stored in lipid droplets, LD) and phospholipids (with the exception of PE, which occurs in the mitochondria and Golgi) occurs in the ER. Fluorescence microscopy images of Opi1 localization courtesy of Yu-Fang Chang, Henry Laboratory, Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY.](317fig3){#fig3}

![Regulation of phospholipid synthesis by soluble lipid precursors and metabolites. The diagram shows the major steps in the synthesis of phospholipids. The enzymes that are biochemically regulated by phospholipid precursors and products are shown. The green arrow designates the stimulation of enzyme activity, whereas the red line designates the inhibition of enzyme activity. Details on the biochemical regulation of these enzymes are discussed in the section *Water soluble precursors of phospholipids, metabolism, and regulatory roles* and in Carman and Han (2009a). See [Figure 2](#fig2){ref-type="fig"} for abbreviations.](317fig4){#fig4}

For example, PA plays a number of signaling roles vital to the regulation of lipid metabolism in yeast ([Figure 3](#fig3){ref-type="fig"}), in addition to its function as precursor to all phospholipids and TAG ([Figure 2](#fig2){ref-type="fig"}). PI synthesis is regulated in response to its precursor, inositol, on several levels ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) and PI also serves as precursor to both phosphatidylinositolphosphates and inositol-containing sphingolipids, both of which are implicated in a wide range of signaling and regulatory activities ([@bib347]; [@bib75], [@bib76]), topics that will not be dealt with in detail in this YeastBook chapter. In addition, the enzymes controlling the metabolism of gycerolipids are localized to specific cellular compartments ([Figure 2](#fig2){ref-type="fig"}; [Tables 1](#t1){ref-type="table"}--[3](#t3){ref-type="table"}), while the lipids themselves are, for the most part, distributed to a much wider range of cellular compartments. Moreover, the regulation of TAG metabolism plays a major role in lipid droplet (LD) formation and depletion ([@bib254]; [@bib299]; [@bib216]; Kohlwein 2010a), a topic that will also be addressed in detail in the chapter on *Lipid Droplets and Peroxisomes*. Thus, detailed knowledge of pathways, gene--enzyme relationships, and subcellular localization of enzymes and pools of lipids and metabolites involved in the synthesis and turnover of glycerolipids ([Figures 2](#fig2){ref-type="fig"}--[4](#fig4){ref-type="fig"}, [Tables 1](#t1){ref-type="table"}--[3](#t3){ref-type="table"}) is essential to the elucidation of the complex mechanisms responsible for their regulation.

###### Glycerolipid synthesis enzymes

  Gene                                                           Ino^−^ or Opi^−^ phenotype   Enzyme                                               Mol mass (kDa)   Isoelectric point   Molecules per cell[*^b^*](#t1n2){ref-type="table-fn"}   Location[*^c^*](#t1n3){ref-type="table-fn"}   Transmembrane domains   Phosphorylation sites[*^d^*](#t1n4){ref-type="table-fn"}
  -------------------------------------------------------------- ---------------------------- ---------------------------------------------------- ---------------- ------------------- ------------------------------------------------------- --------------------------------------------- ----------------------- ----------------------------------------------------------
  *SCT1* (*GAT2*)                                                Ino^−^                       Glycerol-3-P /dihydroxyacetone-P acyltransferase     85.7             7.27                1050                                                    ER                                            4                       Few
  *GPT2* (*GAT1*)                                                ---                          Glycerol-3-P /dihydroxyacetone-P acyltransferase     83.6             10.3                3100                                                    ER, lipid droplets                            4                       Several
  *AYR1*                                                         ---                          Acyl DHAP reductase                                  32.8             9.92                3670                                                    ER, lipid droplets                            None                    None
  *SLC1*                                                         ---                          LysoPA/Acylglycerol-3-P acyltransferase              33.8             10.41               ND                                                      ER, lipid droplets                            1                       None
  *ALE1* (*SLC4,LPT1,LCA1*)                                      ---                          LysoPA/Acylglycerol-3-P acyltransferase              72.2             10.3                ND                                                      ER                                            7                       Several
  *PSI1* (*CST26*)                                               ---                          LysoPI acyltransferase                               45.5             10.15               2010                                                    ER                                            4                       None
  *TAZ1*                                                         ---                          LysoPC acyltransferase/ monolysoCL acyltransferase   44.2             9.38                1340                                                    Mitochondria                                  None                    None
  ***CDS1* (*CDG1*)**[*^a^*](#t1n1){ref-type="table-fn"}         Opi^−^                       CDP-DAG synthase                                     51.8             8.64                ND                                                      ER, mitochondria                              6                       Few
  ***CHO1* (*PSS1*)**[*^a^*](#t1n1){ref-type="table-fn"}         Opi^−^                       PS synthase                                          30.8             6.23                ND                                                      ER                                            2                       Several
  ***PSD1***[*^a^*](#t1n1){ref-type="table-fn"}                  Opi^−^                       PS decarboxylase                                     56.6             9.84                1080                                                    Mitochondria                                  None                    None
  *PSD2*                                                         ---                          PS decarboxylase                                     130              7.85                ND                                                      Vacuole, endomembranes                        None                    Few
  ***CHO2* (*PEM1*)**[*^a^*](#t1n1){ref-type="table-fn"}         Opi^−^                       PE methyltransferase                                 101.2            8.56                1810                                                    ER                                            8                       Few
  ***OPI3* (*PEM2*)**[*^a^*](#t1n1){ref-type="table-fn"}         Opi^−^                       Phospholipid methyltransferase                       23.1             9.6                 5890                                                    ER, mitochondria                              None                    None
  *PAH1* (*SMP2*)                                                ---                          PA phosphatase                                       95               4.68                3910                                                    Cytoplasm, ER                                 None                    Several
  *DGK1* (*HSD1*)                                                ---                          DAG kinase                                           32.8             9.48                784                                                     ER                                            4                       Few
  ***EKI1***[*^a^*](#t1n1){ref-type="table-fn"}                  ---                          Ethanolamine kinase                                  61.6             5.69                3420                                                    Cytoplasm                                     None                    Few
  *ECT1* (*MUQ1*)                                                ---                          Ethanolamine-P cytidylyltransferase                  36.8             6.44                4700                                                    Cytoplasm                                     None                    None
  ***EPT1***[*^a^*](#t1n1){ref-type="table-fn"}                  ---                          Ethanolamine/choline phosphotransferase              44.5             6.5                 ND                                                      ER                                            7                       None
  ***CKI1***[*^a^*](#t1n1){ref-type="table-fn"}                  ---                          Choline kinase                                       66.3             5.43                3930                                                    Cytoplasm                                     None                    Several
  ***PCT1* (*CCT1,BSR2*)**[*^a^*](#t1n1){ref-type="table-fn"}    Opi^−^                       Choline-P cytidylyltransferase                       49.4             9.26                3050                                                    Cytoplasm, nucleus                            None                    Several
  ***CPT1***[*^a^*](#t1n1){ref-type="table-fn"}                  ---                          Choline phosphotransferase                           44.8             6.57                981                                                     Membrane                                      8                       None
  *PGS1* (*PEL1*)                                                ---                          PGP synthase                                         59.3             10.5                ND                                                      Mitochondria                                  None                    None
  *GEP4*                                                         ---                          PGP phosphatase                                      20.9             9.18                ND                                                      Mitochondria                                  None                    None
  *CRD1* (*CLS1*)                                                ---                          CL synthase                                          32               10.55               876                                                     Mitochondria                                  3                       None
  *PIS1*                                                         Ino^−^                       PI synthase                                          24.8             8.92                3810                                                    ER                                            3                       None
  *LSB6*                                                         ---                          PI 4-kinase                                          70.2             6.68                57                                                      Plasma membrane, vacuole membrane             None                    None
  *STT4*                                                         Ino^−^                       PI 4-kinase                                          214.6            7.44                846                                                     Plasma membrane                               None                    Few
  *PIK1*                                                         ---                          PI 4-kinase                                          119.9            6.46                1600                                                    Plasma membrane, nucleus, Golgi               None                    Several
  *VPS34* (*END12,PEP15,VPL7,VPT29,STT8,VPS7*)                   Opi^−^                       PI 3-kinase                                          100.9            7.79                1080                                                    Vacuole                                       None                    None
  *MSS4*                                                         Ino^−^                       PI 4-P 5-kinase                                      89.3             10.13               ND                                                      Cytoplasm                                     None                    Several
  *FAB1* (*SVL7*)                                                Ino^−^                       PI 3-P 5-kinase                                      257.4            8.45                149                                                     Vacuole                                       None                    Several
  ***DGA1***[*^a^*](#t1n1){ref-type="table-fn"}                  ---                          Acyl-CoA diacylglycerol acyltransferase              47.7             10.39               907                                                     ER, lipid droplets                            1                       Few
  ***LRO1***[*^a^*](#t1n1){ref-type="table-fn"}                  ---                          Phospholipid diacylglycerol acyltransferase          75.3             6.67                ND                                                      ER                                            1                       Few
  ***ARE1* (*SAT2*)**[*^a^*](#t1n1){ref-type="table-fn"}         ---                          Acyl-CoA sterol acyltransferase                      71.6             8.27                ND                                                      ER                                            9                       Several
  ***ARE2* (*SAT1*)**[*^a^*](#t1n1){ref-type="table-fn"}         ---                          Acyl-CoA sterol acyltransferase                      74.0             7.71                279                                                     ER                                            9                       Several
  **Phospholipid synthesis regulatory proteins**                                                                                                                                                                                                                                                                      
  ***INO2* (*DIE1, SCS1*)**[*^a^*](#t1n1){ref-type="table-fn"}   Ino^−^                       Transcriptional activator                            34.2             6.23                784                                                     Nucleus                                       None                    None
  *INO4*                                                         Ino^−^                       Transcriptional activator                            17.4             10.21               521                                                     Nucleus, cytoplasm                            None                    None
  *OPI1*                                                         Opi^−^                       Transcriptional repressor                            46               4.87                1280                                                    Nuclear/ER membrane                           None                    Few

Much of the information in the table may be found in the *Saccharomyces* Genome Database. Ino^−^, inositol auxotrophy; Opi^−^, inositol excretion; ND, not determined.

Genes containing the UAS~INO~ element and regulated by the Ino2-Ino4-Opi1 circuit. The names in parentheses are aliases.

[@bib116].

[@bib135]; [@bib215]; [@bib168]; [@bib258].

[@bib229]; [@bib26].

###### Glycerolipid precursor enzymes and transporters

  Gene                                                               Ino^−^ or Opi^−^ phenotype   Enzyme                                                 Mol mass (kDa)   Isoelectric point   Molecules per cell[*^b^*](#t2n2){ref-type="table-fn"}   Location[*^c^*](#t2n3){ref-type="table-fn"}   Transmembrane domains   Phosphorylation sites[*^d^*](#t2n4){ref-type="table-fn"}
  ------------------------------------------------------------------ ---------------------------- ------------------------------------------------------ ---------------- ------------------- ------------------------------------------------------- --------------------------------------------- ----------------------- ----------------------------------------------------------
  ***ACC1* (*ABP2,FAS3,MTR7*)**[*^a^*](#t2n1){ref-type="table-fn"}   ---                          Acetyl CoA carboxylase                                 250.4            6.22                20,200                                                  Cytoplasm                                     None                    Several
  *HFA1*                                                             ---                          Acetyl CoA carboxylase                                 241.8            8.05                396                                                     Mitochondria                                  None                    Few
  ***FAS1***[*^a^*](#t2n1){ref-type="table-fn"}                      ---                          Fatty acid synthase (β subunit)                        228.7            5.79                91,800                                                  Cytoplasm                                     None                    Several
  ***FAS2***[*^a^*](#t2n1){ref-type="table-fn"}                      ---                          Fatty acid synthase (α subunit)                        206.9            5.21                17,000                                                  Cytoplasm                                     None                    Several
  *ETR1*(*MRF'*)                                                     Ino^−^                       2-Enoyl thioester reductase                            42               9.78                1560                                                    Mitochondria                                  None                    None
  *HTD2* (*RMD12*)                                                   ---                          3-Hydroxyacyl-thioester dehydratase                    33               9                   799                                                     Mitochondria                                  None                    None
  *MCT1*                                                             ---                          Malonyl-CoA:ACP transferase                            40.7             6.9                 1360                                                    Mitochondria                                  None                    None
  *OAR1*                                                             ---                          3-Oxoacyl-ACP reductase                                31.2             9.3                 1760                                                    Mitochondria                                  None                    None
  *ACP1*                                                             ---                          Acyl carrier protein                                   13.9             4.64                60,500                                                  Mitochondria                                  None                    Few
  *PPT2*                                                             ---                          Phosphopantetheine:protein transferase                 19.9             8.46                486                                                     Mitochondria                                  None                    None
  *CEM1*                                                             ---                          β-keto-acyl synthase                                   47.6             8.26                1660                                                    Mitochondria                                  None                    None
  *FAA1*                                                             ---                          Fatty acyl CoA synthetase                              77.8             7.58                7470                                                    ER, lipid droplets                            None                    None
  *FAA2* (*FAM1*)                                                    ---                          Fatty acyl CoA synthetase                              83.4             7.7                 358                                                     Peroxisomes                                   None                    None
  *FAA3*                                                             ---                          Fatty acyl CoA synthetase                              77.9             9.7                 6440                                                    Plasma membrane                               None                    None
  *FAA4*                                                             ---                          Fatty acyl CoA synthetase                              77.2             6.52                31,200                                                  ER, lipid droplets                            None                    None
  *FAT1*                                                             ---                          Fatty acid transporter and fatty acyl CoA synthetase   77.1             8.47                16,900                                                  ER, lipid droplets                            3                       None
  *OLE1* (*MDM2*)                                                    ---                          Δ9 Fatty acid desaturase                               58.4             9.71                ND                                                      ER                                            4                       None
  *ELO1*                                                             ---                          FA elongase, condensing enzyme                         36.2             10.2                937                                                     ER                                            5                       None
  *FEN1* (*ELO2*)                                                    ---                          FA elongase, condensing enzyme                         40.0             10.35               3510                                                    ER                                            7                       Several
  *SUR4* (*ELO3*)                                                    ---                          FA elongase, condensing enzyme                         39.5             10.13               ND                                                      ER                                            6                       None
  *IFA38* (*YBR159w*)                                                ---                          β-keto acyl-CoA reductase                              38.7             10.28               41900                                                   ER                                            1                       None
  *PHS1*                                                             ---                          3-Hydroxy acyl-CoA dehydratase                         24.5             10.84               ND                                                      ER                                            6                       None
  *TSC13*                                                            ---                          Enoyl-CoA reductase                                    36.8             10.38               23600                                                   ER                                            4                       None
  ***INO1*[*^a^*](#t2n1){ref-type="table-fn"} (*APR1*)**             Ino^−^                       Inositol 3-P synthase                                  59.6             5.77                ND                                                      Cytoplasm                                     None                    None
  *INM1*                                                             ---                          Inositol 3-P phosphatase                               32.8             5                   2440                                                    Cytoplasm, nucleus                            None                    None
  *URA7*                                                             Ino^−^                       CTP synthetase                                         64.7             5.93                57,600                                                  Cytoplasm                                     None                    Several
  *URA8*                                                             ---                          CTP synthetase                                         63               6.02                5370                                                    Cytoplasm                                     None                    None
  ***ITR1*[*^a^*](#t2n1){ref-type="table-fn"}**                      Opi^−^                       Inositol transporter                                   63.5             6.51                ND                                                      Plasma membrane                               12                      Several
  *ITR2* (*HRB612*)                                                  ---                          Inositol transporter                                   66.7             8.25                468                                                     Plasma membrane                               12                      None
  ***HNM1* (*CTR1*)**[*^a^*](#t2n1){ref-type="table-fn"}             ---                          Choline transporter                                    62               6.83                ND                                                      Plasma membrane                               12                      Few
  *GIT1*                                                             ---                          GroPIns/GroPCho transporter                            57.3             8.64                ND                                                      Plasma membrane                               11                      None

Much of the information in the table may be found in the *Saccharomyces* Genome Database. Ino^−^, inositol auxotrophy; Opi^−^, inositol excretion; ND, not determined.

Genes containing the UAS~INO~ element and are regulated by the Ino2-Ino4-Opi1 circuit, The names in parentheses are aliases.

[@bib116].

[@bib135]; [@bib215]; [@bib168]; [@bib258].

[@bib229]; [@bib26].

###### Glycerolipid turnover enzymes

  Gene                              Ino^−^ or Opi^−^phenotype   Enzyme                                                                              Mol mass (kDa)   Isoelectric point   Molecules per cell[*^a^*](#t3n1){ref-type="table-fn"}   Locationb[*^b^*](#t3n2){ref-type="table-fn"}   Transmembrane domains   Phosphorylation sites[*^c^*](#t3n3){ref-type="table-fn"}
  --------------------------------- --------------------------- ----------------------------------------------------------------------------------- ---------------- ------------------- ------------------------------------------------------- ---------------------------------------------- ----------------------- ----------------------------------------------------------
  *CLD1*                            ---                         CL specific phospholipase A2                                                        52               10.3                ND                                                      Mitochondria                                   None                    None
  *NTE1*                            Ino^−^                      PC specific phospholipase B                                                         187.1            8.19                521                                                     ER                                             3                       Several
  *PLB1*                            ---                         PC/PE specific phospholipase B                                                      71.6             4.36                ND                                                      Plasma membrane, ER, vesicles, extracellular   None                    None
  *PLB2*                            ---                         Nonspecific phospholipase B                                                         75.4             4.35                623                                                     Plasma membrane, ER, vesicles                  None                    None
  *PLB3*                            ---                         Nonspecific phospholipase B                                                         75               4.7                 ND                                                      Cytoplasm, vacuole, vesicles                   None                    None
  *PLC1*                            ---                         PI 4,5-P~2~ specific phospholipase C                                                110.5            9.84                ND                                                      Cytoplasm                                      None                    Few
  *PGC1*                            ---                         PG specific phospholipase C                                                         37               8.93                3270                                                    Mitochondria                                   None                    None
  *SPO14* (*PLD1*)                  ---                         PC specific phospholipase D                                                         195.2            7.58                49                                                      Cytoplasm                                      None                    Several
  *SAC1* (*RSD1*)                   Ino^−^                      Nonspecific polyphosphoinositide phosphatase                                        71.1             7.75                48,000                                                  ER, Golgi, vacuole                             2                       None
  *INP51* (*SJL1*)                  ---                         PI 4,5-P~2~ phosphatase                                                             108.4            6.7                 98                                                      Cytoplasm                                      None                    None
  *INP52* (*SJL2*)                  ---                         Nonspecific polyphosphoinositide phosphatase                                        133.3            8.97                ND                                                      Actin                                          None                    Several
  *INP53* (*SJL3, SOP2*)            ---                         Nonspecific polyphosphoinositide phosphatase                                        124.6            7.18                1520                                                    Actin                                          None                    Several
  *INP54*                           ---                         PI 4,5-P~2~ phosphatase                                                             43.8             7.6                 1200                                                    ER                                             None                    None
  *YRM1*                            ---                         PI 3-P phosphatase                                                                  91               7.19                125                                                     Cytoplasm                                      None                    Few
  [*FIG4*](#fig4){ref-type="fig"}   ---                         PI 3,5-P~2~ phosphatase                                                             101.7            5.52                339                                                     Vacuole                                        None                    None
  *DPP1* (*ZRG1*)                   ---                         DGPP phosphatase/nonspecific lipid phosphate phosphatase                            33.5             6.42                3040                                                    Vacuole                                        5                       Few
  *LPP1*                            ---                         Nonspecific lipid phosphate phosphatase                                             31.5             8.25                300                                                     Golgi                                          4                       None
  *PHM8*                            ---                         LysoPA phosphatase                                                                  37.7             5.14                195                                                     Cytoplasm, nucleus                             None                    None
  *TGL1*                            ---                         Triacylglycerol lipase, sterylester hydrolase                                       63.0             6.83                1470                                                    ER, lipid droplets                             None                    Several
  *TGL2*                            ---                         Acylglycerol lipase                                                                 37.5             8.41                ND                                                      Mitochondria                                   None                    None
  *TGL3*                            ---                         Triacylglycerol lipase, lysoPA acyltransferase                                      73.6             8.50                3210                                                    Lipid droplets                                 1                       Few
  *TGL4*                            ---                         Triacylglycerol lipase, Ca^++^ dependent phospholipase A2, lysoPA acyltransferase   102.7            8.05                195                                                     Lipid droplets                                 None                    Several
  *TGL5*                            ---                         Triacylglycerol lipase, lysoPA acyltransferase                                      84.7             9.84                358                                                     Lipid droplets                                 1                       Several
  *YJU3*                            ---                         Monoacylglycerol lipase                                                             35.6             8.5                 2140                                                    Lipid droplet, ER                              None                    None

Much of the information in the table may be found in the *Saccharomyces* Genome Database. The names in parentheses are aliases. Ino^−^, inositol auxotrophy; ND, not determined.

[@bib116].

[@bib135]; [@bib215]; [@bib168]; [@bib258].

[@bib229]; [@bib26]

Notably, in eukaryotes phospholipids play many vital roles in the biology of the cell that extend beyond lipid metabolism itself. These include roles in membrane trafficking and membrane identity ([@bib375]) and anchoring of membrane proteins ([@bib312]; [@bib293]; [@bib305]), complex topics in their own right, which will be discussed only in brief in this YeastBook chapter. Phospholipids also serve as signaling molecules and as precursors of signaling molecules ([@bib347]). Thus, the advancements in yeast glycerolipid metabolism discussed in this review article also have enormous potential to contribute critical insights into these vital roles of lipids and lipid-mediated signaling in eukaryotic cells.

Pathways of glycerolipid metabolism {#s1}
===================================

Major glycerolipids of *S. cerevisiae* include the phospholipids PC, PE, PI, PS ([Figure 1](#fig1){ref-type="fig"}), phosphatidylglycerol (PG), and cardiolipin (CL) ([@bib301]; [@bib152]; [@bib41]; [@bib280]; [@bib130]; [@bib86]). Minor phospholipids include intermediates such as PA, CDP-diacylglycerol (CDP-DAG), phosphatidylmonomethylethanolamine (PMME), phosphatidyldimethylethanolamine (PDME), the D-3, D-4, and D-5 polyphosphoinositides, and lysophospholipids ([@bib301]; [@bib270]; [@bib347]). TAG and diacylglycerol (DAG) are the major neutral glycerolipids. The fatty acids that are commonly esterified to the glycerophosphate backbone of yeast glycerolipids include palmitic acid (C~16:0~), palmitoleic acid (C~16:1~), stearic acid (C~18:0~), and oleic acid (C~18:1~) ([@bib301]; [@bib152]; [@bib27]; [@bib243]; [@bib240]). The pathways for the synthesis of phospholipids and TAG are shown in [Figure 2](#fig2){ref-type="fig"}. The enzymes and transporters of glycerolipid metabolism and the genes that encode them are listed in Tables [1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"}. The gene--protein relationships shown in the tables have been confirmed by the analysis of gene mutations and/or by the biochemical characterization of the enzymes and transporters ([@bib41]; [@bib123]; [@bib153]; [@bib42]; [@bib24]; [@bib358]; [@bib208]; [@bib40]).

Synthesis and turnover of phospholipids {#s2}
---------------------------------------

In the *de novo* pathways ([Figure 2](#fig2){ref-type="fig"}, [Table 1](#t1){ref-type="table"}), all membrane phospholipids are synthesized from PA, which is derived from glycerol-3-P via lysoPA by two fatty acyl CoA-dependent reactions that are catalyzed in the endoplasmic reticulum (ER) by the *[SCT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000107)*- and *[GPT2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001775)*-encoded glycerol-3-P acyltransferases and the *[SLC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002210)*- and *[ALE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005701)*-encoded lysoPA/lysophospholipid acyltransferases, respectively ([@bib6]; [@bib11]; [@bib407]; [@bib20]; [@bib53]; [@bib174]; [@bib307]). The glycerol-3-P acyltransferase enzymes also utilize dihydroxyacetone-P as a substrate, and the product acyl dihydroxyacetone-P is converted to lysoPA by the lipid droplet (LD) and ER-associated *[AYR1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001386)*-encoded reductase ([@bib9]). At this point in the pathway, PA is partitioned to CDP-DAG, catalyzed by *[CDS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000233)*-encoded CDP-DAG synthase ([@bib45]; [@bib193]; [@bib329]) or to DAG, catalyzed by *[PAH1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)*-encoded PA phosphatase ([@bib141]) ([Figure 1](#fig1){ref-type="fig"}). CDP-DAG synthase activity has been detected in the ER and in mitochondria ([@bib214]), whereas PA phosphatase is a cytosolic enzyme that must associate with membranes to catalyze the dephosphorylation of PA to produce DAG ([@bib141]; Carman and Han 2009a). CDP-DAG and DAG are used to synthesize PE and PC by two alternative routes, namely, the CDP-DAG and Kennedy pathways ([Figure 2](#fig2){ref-type="fig"}). In the CDP-DAG pathway, CDP-DAG is converted to PS by the ER localized *[CHO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000828)*-encoded PS synthase ([@bib13]; [@bib225]; [@bib17]; [@bib201]; [@bib262]). Yeast has two PS decarboxylases encoded, by the *[PSD1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005113)* and *[PSD2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003402)* genes. [Psd1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005113), localized to the inner mitochondrial membrane, accounts for the majority of the enzymatic activity in yeast, while the minor activity, [Psd2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003402), associates with Golgi/vacuole ([@bib66]; [@bib367], [@bib368]; [@bib379]). PE then undergoes three sequential methylation reactions in the ER ([@bib115]), the first of which is catalyzed by the *[CHO2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389)*-encoded PE methyltransferase, while the final two methylations are catalyzed by the *[OPI3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834)*-encoded phospholipid methyltransferase ([@bib204]; [@bib349]; [@bib205]; [@bib245]). The CDP-DAG pathway is the major route for synthesis of PE and PC when wild-type cells are grown in the absence of ethanolamine and choline, and *[cho1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000828)*, *[psd1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005113)[psd2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003402)*, and *[cho2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389)[opi3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834)* mutants defective in this pathway have choline/ethanolamine auxotrophy phenotypes ([@bib12] [@bib349]; [@bib245]; [@bib366]; [@bib368]). PE and PC synthesis in mutants defective in the CDP-DAG pathway can also be supported by exogenously supplied lysoPE, lysoPC, or PC with short acyl chains, which are transported into the cell. LysoPE and lysoPC are acylated by the *[ALE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005701)*-encoded lysophospholipid acyltransferase ([@bib174]; [@bib352]; [@bib308],[@bib307]). Short chain PE and PC are remodeled with C16 and C18 acyl chains prior to incorporation into the membrane ([@bib354]; [@bib73]).

In the Kennedy pathway ([@bib161]), PE and PC are synthesized, respectively, from ethanolamine and choline ([Figure 2](#fig2){ref-type="fig"}, [Table1](#t1){ref-type="table"}). Exogenous ethanolamine and choline are both transported into the cell by the *[HNM1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003045)*-encoded choline/ethanolamine transporter ([@bib260]). The *[EKI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002554)*-encoded ethanolamine kinase ([@bib198]) and the *[CKI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004123)*-encoded choline kinase ([@bib165]) are both cytosolic enzymes, which, respectively, phosphorylate ethanolamine and choline with ATP to form ethanolamine-P and choline-P. Ethanolamine-P may also be derived from sphingolipids by dihydrosphingosine-1-P lyase, encoded by the *[DPL1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002702)* gene ([@bib501]; [@bib323]). These intermediates are then activated with CTP to form CDP-ethanolamine and CDP-choline, respectively, by the *[ECT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003239)*-encoded ethanolamine-P cytidylyltransferase ([@bib251]) and the *[PCT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003434)*-encoded choline-P cytidylyltransferase ([@bib369]), which are associated with the nuclear/ER membrane ([@bib168]; [@bib258]). Finally, the *[EPT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001165)*-encoded ethanolamine phosphotransferase ([@bib160], [@bib162]) and the *[CPT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005074)*-encoded choline phosphotransferase ([@bib159], [@bib161]), respectively, catalyze the reactions of CDP-ethanolamine and CDP-choline with DAG provided by the *[PAH1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)*-encoded PA phosphatase to form PE and PC. [Ept1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001165) will also catalyze the CDP-choline--dependent reaction ([@bib160]). [Cpt1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005074) and [Ept1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001165) have somewhat ambiguous patterns of localization to vesicular structures, but have also been described to localize to mitochondria or ER ([@bib168]; [@bib258]).

The CDP-DAG and Kennedy pathways are both used by wild-type cells, regardless of whether or not ethanolamine and choline are present in the growth medium ([@bib287]; [@bib153]; [@bib198]). In the absence of exogenous choline, this Kennedy pathway precursor may be derived from hydrolysis of PC synthesized by the CDP-DAG pathway and subsequently hydrolyzed by phospholipase D ([@bib287]; [@bib392]) encoded by the *[SPO14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001739)* gene ([@bib311]; [@bib381]). Choline for PC synthesis can also be derived from [Nte1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004524)-catalyzed deacylation ([@bib372]) followed by hydrolysis by [Gde1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006031) to produce choline and glycerophosphate ([@bib97]; [@bib102]; [@bib285]). The activity of a Ca^++^-dependent phospholipase D with preference for PS and PE has been detected ([@bib242]), but the corresponding gene encoding a PE-specific phospholipase D has yet to be identified. Thus, proof that ethanolamine derived from PE is recycled for PE synthesis via the Kennedy pathway is still lacking. Kennedy pathway mutants (*e.g.*, *[cki1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004123)[eki1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002554)* and *[cpt1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005074)[ept1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001165)*) defective in both the CDP-choline and CDP-ethanolamine branches can synthesize PC only by the CDP-DAG pathway ([@bib246]; [@bib253]; [@bib198]). However, unlike the CDP-DAG pathway mutants, the Kennedy pathway mutants do not exhibit any auxotrophic requirements and have an essentially normal complement of phospholipids ([@bib253]; [@bib198]).

In the synthesis of the inositol-containing phospholipids ([Figure 2](#fig2){ref-type="fig"}, [Table 1](#t1){ref-type="table"}), CDP-DAG donates its phosphatidyl moiety to inositol to form PI ([@bib288]; [@bib101]) in a reaction that competes in the ER with PS synthase for their common substrate, CDP-DAG ([@bib194]). While *[PIS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006317)*-encoded PI synthase is essential, a strain expressing a mutant form of [Pis1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006317) with a lower affinity for inositol has been isolated as an inositol auxotroph ([@bib259]; [@bib261]). The inositol used in PI synthesis is either synthesized *de novo* (discussed below) or obtained from the growth medium via the *[ITR1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002905)*- and *[ITR2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005463)*-encoded inositol transporters ([Table 2](#t2){ref-type="table"}) ([@bib263]). Once formed, PI may be converted to PI 3-P by the *[VPS34](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004230)*-encoded PI 3 kinase ([@bib154]; [@bib321]) or to PI 4-P by the PI 4 kinases encoded by *[LSB6](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003636)* (Han G-S *et al.* 2002; [@bib328]), *[STT4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004296)* ([@bib399]), and *[PIK1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005211)* ([@bib103]; [@bib108]). PI 4-P may be further phosphorylated to PI 4,5-P~2~ by the *[MSS4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002616)*-encoded PI 4-P 5 kinase ([@bib400]), whereas PI 3-P may be phosphorylated to PI 3,5-P~2~ by the *[FAB1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001915)*-encoded PI 3-P 5 kinase ([@bib393]). The specific localization of these kinases and the lipids they produce play important roles in signaling, membrane identity, and membrane trafficking ([@bib347]). PI also serves as a precursor in the synthesis of the complex sphingolipids in yeast, which also play essential roles in signaling and membrane function (Dickson and Lester 2002; [@bib75]), topics that are beyond the scope of this YeastBook chapter.

In the synthesis of mitochondrial-specific phospholipids ([Figure 2](#fig2){ref-type="fig"}, [Table1](#t1){ref-type="table"}), CDP-DAG donates its phosphatidyl moiety to glycerol-3-P to form phosphatidylglycerophosphate (PGP) in the reaction catalyzed by the *[PGS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000510)*-encoded PGP synthase ([@bib177]; [@bib48]). PGP is then dephosphorylated to PG by the *[GEP4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001142)*-encoded PGP phosphatase ([@bib274]). The *[CRD1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002301)*-encoded CL synthase ([@bib184]; [@bib49]; [@bib370]) catalyzes the reaction between PG and another molecule of CDP-DAG to generate CL. The *[CLD1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003342)*-encoded cardiolipin-specific phospholipase and the *[TAZ1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006344)*-encoded monolyso cardiolipin acyltransferase, involved in establishing specific unsaturated cardiolipin species, are also specifically associated with the mitochondria ([@bib21]; [@bib29]).

The enzymes that catalyze the turnover of phospholipids include both phospholipases and lipid phosphatases ([Table 3](#t3){ref-type="table"}). *[NTE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004524)*-encoded phospholipase B ([@bib372]; [@bib98], [@bib99]) is an integral ER membrane protein and removes both fatty acids from PC to produce glycerophosphocholine (GroPCho). GroPCho may be re-acylated by an uncharacterized acyltransferase to PC ([@bib343]). The phospholipase B enzymes encoded by *[PLB1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004610)*, *[PLB2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004608)*, and *[PLB3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005371)* catalyze the same type of reaction, but they are not specific and their localization is ambiguous. [Plb1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004610) localizes to the ER, vesicles, the plasma membrane, and the extracellular space and primarily utilizes PC and PE as substrates, whereas [Plb3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005371) is found in vesicles, vacuoles, as well as the cytosol and primarily uses PI as a substrate ([@bib223]; [@bib105]; [@bib247], [@bib248]). The GroPCho and glycerophosphoinositol (GroPIns) produced by the phospholipase B enzymes may be excreted into the growth medium and then transported back into the cell by the *[GIT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000695)*-encoded GroPCho/GroPIns transporter localized in the plasma membrane ([@bib286]; [@bib102]). In turn, these molecules are hydrolyzed by a phosphodiesterase to produce the phospholipid precursor molecules choline and inositol, respectively ([@bib285]). *[PLC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006189)*-encoded phospholipase C is cytosolic and specific for PI 4,5-P~2~ and produces DAG and inositol 1,4,5-trisphosphate ([@bib104]; [@bib398]), and the *[PGC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006127)*-encoded phospholipase C localizes to lipid droplets and mitochondria and is specific for PG and produces DAG and glycerol 3-P ([@bib333]). The *[SPO14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001739)*-encoded cytosolic phospholipase D is specific for PC and produces PA and choline ([@bib311]; [@bib381]). Most phospholipids undergo rapid turnover and acyl-chain remodeling, which yields the typical complex pattern of lipid molecular species found in yeast ([@bib319]; [@bib130]; [@bib86]). This remodeling is governed by specific acyltransferases, such as the *[PSI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000246)*-encoded acyltransferase in the ER that is involved in stearoyl-acylation of PI ([@bib222]), or the *[CLD1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003342)*-encoded cardiolipin-specific phospholipase A in mitochondria ([@bib21]) and the *[TAZ1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006344)*-encoded acyltransferase (yeast tafazzin ortholog; [@bib129]; [@bib359]). Moreover, several enzymes of TAG synthesis and degradation have additional activities, suggesting that they also may play a role in phospholipid acyl-chain remodeling ([@bib299]; [@bib208] [@bib297],[@bib298]).

There are several phosphatase enzymes that catalyze the dephosphorylation of the polyphosphoinositides. Some of these enzymes are specific and some have broad substrate specificity. The *[YMR1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003871)*-encoded ([@bib357]) and *[FIG4](#fig4){ref-type="fig"}*-encoded ([@bib110]) phosphatases are specific for PI 3-P and PI 3,5-P~2~, respectively, whereas *[INP51](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001264)*-encoded (Stolz *et al.* 1998b) and *[INP54](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005426)*-encoded ([@bib384]) phosphatases are specific for PI 4,5-P~2~. The phosphatase encoded by *[SAC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001695)* will utilize PI 3-P, PI 4-P, and PI 3,5-P~2~ ([@bib133]), whereas the phosphatases encoded by *[INP52](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005050)* and *[INP53](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005635)* will utilize any polyphosphoinositide as a substrate (Stolz *et al.* 1998; [@bib133]).

The *[DPP1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002692)*- and *[LPP1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002911)*-encoded lipid phosphate phosphatase enzymes dephosphorylate a broad spectrum of substrates that include DAG pyrophosphate (DGPP), PA, lysoPA, sphingoid-base phosphates, and isoprenoid phosphates ([@bib363], [@bib364]; [@bib94]). While these enzymes may utilize PA as a substrate, they are not involved in the *de novo* synthesis of phospholipids and TAG; the function of which is ascribed to the *[PAH1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)*-encoded PA phosphatase ([@bib141]; Carman and Han 2009a). The *[PHM8](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000839)* gene encodes a lipid phosphatase that is specific for lysoPA and yields monoacylglycerol (MAG) and P~i~ ([@bib303]). *N*-acyl PE is a minor phospholipid species implicated in signaling processes ([@bib248]) and is degraded by the *[FMP30](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006024)*-encoded phospholipase D to *N*-acylethanolamide (NAE), which is related to endocannabinoids (Muccioli *et al.* 2009). NAE may be catabolized by [Yju3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001577), the major MAG lipase in yeast (see below).

Synthesis and turnover of TAG {#s3}
-----------------------------

The pathways for the synthesis of TAG and phospholipids share the same initial steps ([Figure 2](#fig2){ref-type="fig"}; [Table 1](#t1){ref-type="table"}; Kohlwein 2010b). Indeed, TAG is derived from the phospholipid, PA. The *[PAH1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)*-encoded PA phosphatase provides DAG, which is acylated by the *[DGA1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771)*- and *[LRO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005291)*-encoded acyl-CoA--dependent and phospholipid-dependent diacylglycerol acyltransferases, respectively, to TAG ([@bib268]; [@bib336]; [@bib208]). The *[ARE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000644)*- and *[ARE2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005302)*-encoded sterol acyltransferases utilize acyl-CoA but contribute only marginally to TAG synthesis from DAG ([@bib394]). Notably, deletion of both *[DGA1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771)* and *[LRO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005291)* genes does not result in a readily detectable growth phenotype in wild-type cells, indicating that TAG synthesis is not essential ([@bib268]; [@bib336]). Similarly, simultaneous deletion of the *[ARE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000644)* and *[ARE2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005302)* genes does not impair cell growth ([@bib394]). Even the *[dga1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771)[lro1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005291)[are1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000644)[are2Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005302)* quadruple mutant that lacks both TAG and steryl esters, and has no lipid droplets (LD), exhibits only a slight extension of the lag phase after recovery from quiescence ([@bib291]). The *[dga1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771)[lro1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005291)[are1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000644)[are2Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005302)* quadruple mutant, however, does exhibit a defect in sterol synthesis ([@bib337]) and is highly sensitive to unsaturated fatty acid (FA) supplementation ([@bib107]; [@bib291]). Strikingly, provision of exogenous unsaturated FA in the absence of TAG synthesis leads to respiration-dependent cell necrosis ([@bib310]), challenging the dogma that lipid-induced cell death is exclusively apoptotic. The *[dga1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771)[lro1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005291)[are1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000644)[are2Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005302)* quadruple mutant also displays an Ino^--^ phenotype at elevated growth temperature, indicative of altered *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression and/or defective PI synthesis ([@bib114]), ER stress induced by tunicamycin, which inhibits protein glycosylation and stimulates LD formation in wild-type cells. However, the *[dga1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771)[lro1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005291)[are1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000644)[are2Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005302)* quadruple mutant is no more sensitive to tunicamycin than wild type, indicating that LD formation is not protective against this form of stress ([@bib96]). [Dga1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771) and [Lro1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005291) acyltransferase-dependent TAG synthesis, on the other hand, is required for growth at semipermissive temperatures in the absence of inositol in the *[sec13](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004198)^ts^-1* mutant, defective in COPII vesicle budding from the ER. When shifted to higher growth temperature, the *[sec13](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004198)^ts^* mutant channels PA and DAG precursors from phospholipid into TAG, which apparently provides a degree of protection from the secretory stress caused by a block in membrane trafficking ([@bib113]).

TAG hydrolysis ([Figure 2](#fig2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}) clearly contributes lipid precursors that are essential to the resumption of growth upon exit from stationary phase ([@bib216]; [@bib208]). TAG degradation provides substrates for the synthesis of phospholipids and sphingolipids ([@bib300]), which are required for efficient cell cycle progression upon exit from quiescence ([@bib216]). Degradation of TAG is catalyzed by *[TGL1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001623)*-, *[TGL3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004930)*-, *[TGL4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797)*-, and *[TGL5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005607)*-encoded TAG lipases, all of which are localized to LD ([@bib7], [@bib8]; [@bib175]; [@bib217]; [@bib299]; [@bib216]; [@bib208]). [Tgl1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001623) harbors the canonical lipase catalytic triad, consisting of serine201, aspartate369 and histidine396 (Jandrositz *et al.* 2005). In contrast, [Tgl3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004930), [Tgl4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797), and [Tgl5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005607) (and also [Nte1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004524), see above) are members of the patatin domain-containing family of (phospho) lipases, characterized by a catalytic diad of serine and aspartate ([@bib217]). The substrate specificities of the [Tgl3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004930), [Tgl4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797), and [Tgl5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005607) TAG lipases differ. [Tgl5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005607) preferentially hydrolyses TAG molecular species harboring very long chain fatty acids (VLCFA) ([@bib8]), while [Tgl3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004930) also accepts DAG as a substrate in addition to TAG ([@bib217]). [Tgl3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004930), [Tgl4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797), and [Tgl5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005607) also possess lysoPA acyltransferase activities, and [Tgl4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797) additionally functions as a Ca^++^-dependent phospholipase [A2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000692) and steryl ester hydrolase ([@bib297],[@bib298]). Although [Tgl1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001623) also contributes to TAG hydrolysis, its major activity is as a steryl ester hydrolase, in conjunction with the *[YEH1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003935)*- and *[YEH2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004010)*-encoded enzymes ([@bib175]; [@bib206]). *[TGL2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002465)* encodes an acylglycerol lipase localized to mitochondria, but its role in TAG homeostasis has not been clarified yet ([@bib136]). *[YJU3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001577)* encodes the major monoacylglycerol (MAG) lipase in yeast ([@bib151]), but *[yju3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001577)*Δ mutants do not display any detectable growth phenotype when tested under multiple conditions ([@bib151]).

Stationary phase cells shifted into fresh media rapidly initiate TAG and steryl ester breakdown, which leads to almost full depletion of cellular LD pools within 4--6 hr in lag phase. This initial phase of TAG breakdown is governed by the activity of *[TGL3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004930)*- and *[TGL4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797)*-encoded lipases on LD and the *[tgl3Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004930)[tgl4Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797)* mutant strain exhibits a delay in entering vegetative growth during exit from stationary phase ([@bib217]). [Tgl4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797) is constitutively present on LD and activation of [Tgl4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001797) by [Cdc28p](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000364)-dependent phosphorylation is involved in TAG lipolysis that contributes to bud formation exiting from stasis ([@bib216]). Resumption of growth following stasis is also dependent on the *[DGK1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005838)*-encoded DAG kinase. In comparison to wild-type cells, stationary phase *[dgk1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005838)* cells fail to initiate growth when *de novo* FA synthesis is impaired. The *[dgk1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005838)* mutant also fails to mobilize TAG under these conditions and accumulates TAG, phenotypes that are partially suppressed by the *[pah1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)* mutation or by channeling DAG into PC synthesis when choline is present ([@bib92]).

TAG synthesis and breakdown are also coordinated with phospholipid metabolism during logarithmic growth. Mutants with defects in TAG hydrolysis exhibit decreased synthesis of inositol containing sphingolipids and decreased PC and PI content during active growth ([@bib300]). Furthermore, mutants defective in synthesis or hydrolysis of TAG exhibit reduced capacity to restore cellular levels of PI when exogenous inositol is resupplied following an interval of inositol starvation during logarithmic growth. Under these conditions, alterations in the synthesis of inositol-containing sphingolipids are also observed in the *[dga1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771)[lro1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005291)[are1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000644)[are2Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005302)* strain ([@bib114]).

Glycerolipid precursors {#s4}
-----------------------

### Fatty acid synthesis and regulation: {#s5}

The FA that are esterified to phospholipids and TAG are derived from *de novo* synthesis, the growth medium, and from lipid turnover ([@bib358]). The spectrum of FA in yeast consists mainly of C~16~ and C~18~ FA that are either saturated or monounsaturated, harboring a single double bond between carbon atoms 9 and 10 (Δ9 desaturation). Whereas *de novo* FA synthesis mostly takes place in the cytosol, all the enzymes involved in FA desaturation and elongation are associated with the ER membrane ([Table 2](#t2){ref-type="table"}) ([@bib358]).

Minor FA species are C~12~, C~14~, and very long chain FA, up to C~26~. However, FA compositions vary substantially between strains and are also dependent on cultivation conditions ([@bib240]). Two different FA synthesis pathways exist in yeast, as in mammalian cells ([@bib358]): the major cytosolic pathway, which resembles the "eukaryotic" type I pathway and is responsible for the bulk synthesis of all major FA, and the mitochondrial (type II pathway), which is organized similarly to the bacterial FA biosynthetic pathway ([@bib157]). The latter is believed to synthesize FA up to C~8~ carbons, which serve as precursors for the synthesis of lipoic acid. Cytosolic FA synthesis is initiated by the *[ACC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299)*-encoded acetyl-CoA carboxylase, which synthesizes malonyl-CoA from acetyl-CoA ([@bib3]; [@bib150]). This reaction requires a covalently bound biotin prosthetic group, which is attached to lysine735 in the biotin-carrier domain of [Acc1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299) by the *[BPL1](http://www.yeastgenome.org/cgi-bin/locus.fpl?locus=BPL1&rm=display_result)*-encoded biotin:apoprotein ligase. The FA synthase complex is composed of two subunits, encoded by *[FAS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)* ([Fas1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665), β-subunit) and *[FAS2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152)* ([Fas2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152), α-subunit) and is organized as an α6/β6 heterooligomeric complex ([@bib219]; [@bib327]; [@bib57]). [Fas2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152) carries a pantetheine prostetic group on the acyl-carrier protein (ACP) domain, which is a central element in a cycling series of reactions. In a first condensation step, malonyl-CoA is condensed with pantetheine-bound acetyl-CoA to form 3-keto-acyl-ACP, which is reduced to 3-hydroxyacyl-ACP, dehydrated to 2,3-*trans*-enoyl-ACP, and further reduced to acyl~(C+2)~-ACP. Both reduction steps require NADPH and, as a result, FA synthesis is a major consumer of this dinucleotide. This multistep process results in the addition of two carbon units to the growing FA chain and cycles up to seven times, resulting in acyl-chains typically of 16 carbon atoms. The newly formed FA is transferred to coenzyme A, to yield cytosolic long chain acyl-CoA ([@bib358]). Acyl-CoA molecules are precursors for all acylation reactions involved in the synthesis of phospholipids, TAG, long chain bases, ceramide, and steryl esters, and also serve as precursors in protein acylation. The acyl-CoAs, whether derived from FA *de novo* synthesis or lipid recycling, are subject to elongation and desaturation, yielding the typical pattern of saturated and unsaturated FA species (see below). Yeast also contains an *[ACB1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003269)*-encoded acyl-CoA binding protein, which plays an important regulatory function in delivering acyl-CoA into various pathways ([@bib316]; [@bib106]; [@bib91]; [@bib309]). Mitochondrial FA synthesis involves enzymatic steps similar to those catalyzed by the cytosolic FAS complex. However, in contrast to cytosolic FA synthesis, but resembling archae- and eubacterial type II fatty acid synthase, the reactions of FA synthesis in mitochondria are catalyzed by individual polypeptides, encoded by separate genes ([@bib157]).

Defects in the *[FAS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)* or *[FAS2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152)* genes encoding cytosolic FA synthase lead to FA auxotrophy and can typically be rescued by the addition of exogenous C~14~ or C~16~ FAs. However, defects in *[ACC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299)* ([@bib150]) and *BPL2* are lethal and cannot be suppressed by the addition of long chain FA. The essential role of these genes, when exogenous C~14~ and C~16~ FAs are present, is most likely the requirement for malonyl-CoA in the synthesis of essential VLCFA, which are components of glycerophosphoinositol (GPI) anchors and sphingolipids ([@bib293]; [@bib75]; [@bib76]). The synthesis of VLCFAs is accomplished by an ER membrane-localized elongase complex that acts on long chain acyl-CoA, consisting of the condensing enzymes encoded by *[ELO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003732)*, *[ELO2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000630)*, and *[ELO3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004364)* ([@bib269]), the β-ketoacyl-CoA reductase encoded by gene *[YBR159w](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000363)* (Han *et al.* 2002), the dehydratase encoded by *[PHS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003633)* ([@bib73]; [@bib197]), and the enoyl-CoA reductase, encoded by *[TSC13](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002173)* ([@bib209]). [Tsc13](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002173) accumulates within a specialized region of the ER in juxtaposition to the vacuole, termed the nucleus-vacuole junction ([@bib281]) through interaction with [Osh1p](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000081) and [Nvj1p](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001238) ([@bib220]). The physiological role for a localization of just one component of the FA elongation complex to this subregion of the ER is currently unclear, but indicates a role for VLCFA in the formation of microautophagic vesicles involved in piecemeal autophagy of the nucleus ([@bib220]). Triple mutations in all three condensing enzyme genes as well as mutations in *[PHS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003633)* or *[TSC13](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002173)* are lethal, further supporting the notion that VLCFAs are essential in yeast. Yeast also harbors a single FA Δ9-desaturase encoded by *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)*, which localizes to the ER ([@bib348]) and mutants defective in [Ole1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023) require exogenous C~16:1~ or C~18:1~ FA for growth. Since FA desaturation is an oxygen-dependent process (see below), growth of yeast under anaerobic conditions also requires the supplementation of these unsaturated FA.

In the absence of *de novo* FA synthesis or desaturation, as in *[fas1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)*, *[fas2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152)*, or *[ole1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* mutants, and in wild-type cells under anaerobic conditions, cellular growth is dependent on an exogenous supply of FA. Under these conditions, the activity of acyl-CoA synthetases ([Table 2](#t2){ref-type="table"}), encoded by *[FAA1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005844)*, *[FAA2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000817)*, *[FAA3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001271)*, *[FAA4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004860)*, and *[FAT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000245)* ([@bib83]; [@bib149]; [@bib185],[@bib186]; [@bib382]; [@bib62]; [@bib24]) is also required. The acyl-CoA synthetases activate free FA with coenzyme A in an ATP-dependent reaction, and are also believed to be required for FA uptake into yeast cells ([@bib90]; [@bib24]; [@bib266]). Acyl-CoA synthetases differ in their substrate specificity and subcellular localization and are present in the ER membrane, plasma membrane, peroxisome, and LD ([@bib258]; [@bib24]). The acyl-CoA synthetase [Faa2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000817) and the enzymes for FA β-oxidation, a cyclic series of reactions breaking down FA into acetyl-CoA and generating FADH~2~ and NADH, are localized to the peroxisomes (planned YeastBook chapter "Lipid particles and peroxisomes" by Kohlwein and van der Klei). FA uptake into yeast cells is also mediated by an endocytotic mechanism that requires the activity of [Ypk1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001609), the yeast ortholog of the human serum- and glucocorticoid-induced kinase (Jacquier and Schneiter 2010). In the absence of acyl-CoA synthetases, FA released by lipid turnover (see above) cannot be activated and utilized for lipid synthesis. For this reason, mutants lacking these activities excrete FA ([@bib315]).

FA synthesis is regulated at multiple levels ([@bib358]). *[ACC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299)*, *[FAS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)*, and *[FAS2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152)* expression is under control of an UAS~INO~ element and coregulated with genes involved in phospholipid synthesis ([@bib56]; [@bib324]) (see below). *[ACC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299)* expression is also regulated by the SAGA protein complex and TFIID ([@bib169]) and may therefore depend on histone acetylation. *[ACC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299)* expression was also found to fluctuate during the cell division cycle, with a peak of expression in early G1 phase ([@bib58]). Compensatory changes in *[ACC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299)* expression in mutants defective in [Acc1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299) activity indicate an autoregulatory loop ([@bib331]). Expression of the *[FAS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)* and *[FAS2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152)* genes is regulated by the transcription factors [Gcr1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005996), [Reb1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000253), [Rap1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005160), and [Abf1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001595) ([@bib325]; [@bib123]) and repressed by long chain FA ([@bib56]). *[FAS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)* is also regulated by the SAGA complex and TFIID, and both genes show cell cycle-dependent expression, with a peak level at M/G1 ([@bib339]; [@bib169]).

[Acc1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299) enzyme activity is greatly elevated in the *[snf1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002885)*Δ mutant and the data are consistent with [Acc1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299) being a substrate of AMP-activated protein kinase, encoded by the *[SNF1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002885)* ([@bib387]; [@bib331]). [Snf1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002885) also regulates chromatin by phosphorylating histones among other proteins and, therefore, has multiple effects on expression of genes, including *[ACC1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299)*, *[FAS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)*, and *[FAS2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152)*. Notably, *[FAS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)* and *[FAS2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152)* promoter sequences differ, and the stoichiometry of the FAS complex is established both by the level of *[FAS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)* gene expression and [Fas1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665) protein abundance ([@bib324]; [@bib383]; [@bib358]). Excess of either protein is rapidly eliminated by degradation via vacuolar proteases ([Fas1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001665)) or ubiquitination and proteasomal digestion ([Fas2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006152)), respectively ([@bib289]).

Knowledge about the regulation of FA elongation leading to VLCFA synthesis is limited. Microarray experiments have shown that *[ELO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003732)* expression is upregulated in the presence of myristic acid (C~14:0~), consistent with the preference of the [Elo1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003732) protein for this FA ([@bib362]). Expression of *[ELO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003732)*, *[ELO2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000630)*, and *[ELO3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004364)* genes also responds to stationary phase, nitrogen limitation, glycosylation defects, or α-factor treatment, indicating a regulatory cross-talk between nutritional state and cell proliferation to VLCFA synthesis ([@bib111]).

[Ole1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023) is a nonheme iron-containing integral ER membrane protein ([Table 2](#t2){ref-type="table"}), which harbors an intrinsic cytochrome b~5~ domain as an electron carrier ([@bib240]). To subtract two electrons and two protons from the saturated acyl-chain and transfer them to oxygen, [Ole1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023) activity is complemented by the activity of an NADH cytochrome b~5~ reductase (dehydrogenase) that is also localized to the ER. Desaturation of FA by [Ole1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023) is a highly regulated, oxygen-requiring process ([@bib240]), which is discussed in detail in the section below on cell biology of lipids.

### Water soluble precursors of phospholipids, metabolism, and regulatory roles: {#s6}

A number of water-soluble molecules used in phospholipid synthesis, including inositol, choline, ethanolamine, serine, CTP, and S-adenosyl methionine (AdoMet) and the enzymes involved in these reactions are largely cytosolic ([Table 2](#t2){ref-type="table"}). However, choline and ethanolamine are produced in yeast in the context of ongoing synthesis and turnover of PE and PC in the membranes as discussed above. Considerable attention has been paid to inositol and CTP, which have major regulatory roles in phospholipid metabolism. The effects of inositol on transcriptional regulation UAS~INO~-containing phospholipid biosynthetic genes controlled by the [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) repressor are shown in [Figure 3](#fig3){ref-type="fig"} and will be discussed in a subsequent section. The regulatory effects of the soluble metabolites inositol, CTP, and S-adenosyl homocysteine (AdoHcy) on enzyme activity and metabolic flux in the CDP-DAG pathway ([Figure 4](#fig4){ref-type="fig"}) are discussed here.

Inositol is the precursor to PI ([Figure 2](#fig2){ref-type="fig"}), which is essential to the synthesis of polyphosphoinositides ([@bib347]), sphingolipids ([@bib68]; [@bib75], [@bib76]), and GPI anchors ([@bib293]). Inositol is derived from glucose-6-P via the reactions catalyzed by the cytosolic *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)*-encoded inositol-3-P synthase ([@bib80]; [@bib202]; [@bib72]) and the *[INM1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001088)*-encoded inositol-3-P phosphatase ([@bib255]). Exogenously supplied inositol stimulates PI synthase and inhibits PS synthase activity, alleviating the competition with PI synthase for their common substrate, CDP-DAG ([Figure 4](#fig4){ref-type="fig"}). The presence of exogenous inositol leads to increased PI synthesis and reduced levels of both CDP-DAG and its precursor PA in wild-type cells ([@bib194]; [@bib236]). TAG, which is derived from PA by the action of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) ([Figure 2](#fig2){ref-type="fig"}), is decreased in the presence of inositol and increases in its absence ([@bib412], 2011). In addition, the levels of the complex sphingolipids, which are derived from PI, are reduced when cells are deprived of inositol and increase when inositol is supplied (Becker and Lester 1977; [@bib147]; [@bib183]). The changes that occur in phospholipid synthesis and composition in response to exogenous serine ([@bib194]) and choline ([@bib412]) are much less dramatic than the effects of exogenous inositol. However, when inositol is present in the growth medium, serine ([@bib415]), ethanolamine, and choline (Poole *et al.* 1986) result in the reduction of the activities of PS synthase and CDP-DAG synthase at the transcriptional level (see below). Exogenous choline also results in a dramatic change in the rate and mechanism of PC turnover, leading to a switch from a phospholipase D to a phospholipase B-mediated route (Dowd *et al.* 2001). The phospholipase responsible for turnover of PC under these conditions is [Nte1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004524) ([@bib372]).

CTP is derived from UTP by the cytosolic *[URA7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000135)*- and *[URA8](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003864)*-encoded CTP synthetase enzymes ([@bib277], [@bib278]).

The nucleotide CTP plays a critical role in phospholipid synthesis as the direct precursor of the high-energy intermediates CDP-DAG, CDP-choline, and CDP-ethanolamine that are used in the CDP-DAG and Kennedy pathways ([Figure 2](#fig2){ref-type="fig"}) ([@bib50]). It is also used as the phosphate donor for the synthesis of PA by DAG kinase ([@bib144]). CTP synthetase ([@bib277], [@bib278]) that produces CTP is allosterically inhibited by the product ([@bib396]; [@bib256]), and this regulation ultimately determines the intracellular concentration of CTP ([@bib396]; [@bib244]). CTP inhibits the CTP synthetase activity by increasing the positive cooperativity of the enzyme for UTP, and at the same time by decreasing the affinity for UTP ([@bib396]; [@bib256]). However, CTP synthetases containing an E161K mutation are less sensitive to CTP product inhibition ([@bib275]), and cells expressing the mutant enzymes exhibit a 6- to 15-fold increase in the CTP level ([@bib275]). They also show alterations in the synthesis of membrane phospholipids, which include a decrease in the amounts of PS and increases in the amounts of PC, PE, and PA ([@bib275]). The decrease in the amount of PS results from direct inhibition of PS synthase activity by CTP ([@bib244]), and this inhibition favors the synthesis of phospholipids by the Kennedy pathway ([Figure 4](#fig4){ref-type="fig"}). The increase in PC synthesis is ascribed to a higher utilization of the CDP-choline branch of the Kennedy pathway due to the stimulation of choline P cytidylyltransferase activity ([@bib244]; [@bib275]) by increased substrate availability of CTP ([@bib244]; [@bib195]). Likewise, the increase in PE synthesis could be attributed to stimulation of ethanolamine-P cytidylyltransferase activity. The increase in PA content may result from the stimulation of DAG kinase activity by increased availability of its substrate CTP ([@bib144]). CTP also inhibits the activity of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) ([@bib388]), another factor that contributes to an elevation of PA content. The cells expressing the E161K mutant CTP synthase excrete inositol ([@bib275]), a characteristic phenotype that typifies the misregulation of UAS~INO~-containing phospholipid synthesis genes (see below) in cells that accumulate an excess of PA ([@bib43]). It is unclear whether UAS~INO~-containing genes in the CDP-DAG and Kennedy pathways are derepressed in CTP overproducing cells, but the overriding regulation that governs the utilization of the two pathways appears to be biochemical in nature.

AdoHcy is a product of the AdoMet-dependent methylation reactions that are catalyzed by [Cho2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389) and [Opi3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834) in the CDP-DAG pathway ([Figure 2](#fig2){ref-type="fig"}). *[SAH1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000845)*-encoded AdoHcy hydrolase ([@bib239]) requires NADH for the hydrolytic breakdown of AdoHcy to adenosine and homocysteine ([@bib351]). AdoHcy ([Figure 4](#fig4){ref-type="fig"}) is a competitive inhibitor of the phospholipid methyltransferase enzymes ([@bib115]). Thus, down-regulation of the AdoHcy hydrolase causes the accumulation of AdoHcy and the inhibition of PC synthesis, which leads to an increase in PA content and consequently, as described below, to the derepression of UAS~INO~-containing genes ([@bib239]). Although the effects of AdoHcy on phospholipid composition have not been addressed, its accumulation causes an increase in TAG synthesis and LD content ([@bib239]), further underscoring the metabolic interconnection between phospholipid and TAG homeostasis discussed above.

Cell Biology of Lipids {#s7}
======================

In yeast, most subcellular membranes are composed of similar glycerophospholipid classes but the quantitative phospholipid composition of subcellular organelles differs substantially ([@bib319]). Moreover, as described above, multiple cellular organelles and compartments contribute to glycerolipid metabolism ([Figure 2](#fig2){ref-type="fig"}, [Tables 1](#t1){ref-type="table"}--[3](#t3){ref-type="table"}). While multiple compartments contribute to lipid synthesis in yeast ([@bib258]), most reactions are confined to single membrane compartments. Thus, extensive regulated flux of lipids, across and among individual membranes and organelles, is required to enable the cell to adjust lipid composition in specific compartments under changing growth conditions. A number of mechanisms involved in these complex interactions have been identified.

For example, a set of membrane-bound flippases are known to govern transmembrane movement of phospholipids ([@bib294]; [@bib163]). Intermembrane transfer of lipids is facilitated by a family of proteins, termed oxysterol-binding protein (OSBP) related proteins (ORP), of which seven members, [Osh1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000081)--[7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001043), with overlapping functions, exist in yeast ([@bib19]). Some of the yeast Osh proteins have been localized to membrane contacts sites ([@bib228]; [@bib302]). While none of these genes individually are essential, simultaneous deletion of all seven *OSH* genes is lethal and conditional alleles, following a shift to restrictive conditions, result in pleiotropic effects on vesicular trafficking and phospholipid and sterol composition of membranes, as do combinations of individual deletions ([@bib19]; [@bib95]). The six members of the [Sec14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004684) superfamily constitute another major class of proteins involved in sensing and regulating membrane lipid composition ([@bib127]; [@bib18]). The five [Sec14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004684) homologs ([Sfh1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001574)--[5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003681)) share 28--76% similarity to [Sec14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004684) ([@bib127]) and localize to multiple subcellular organelles ([@bib317]). [Sec14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004684), which performs an essential function at the Golgi, was originally identified as a PI/PC transfer protein, but its role in establishing phospholipid homeostasis is complex ([@bib18]).

In some instances, movement of lipids between membrane compartments is required to carry out a sequence of reactions. For example, PS is synthesized in the ER, but the major PS decarboxylase, [Psd1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005113), is located in the mitochondria ([Figure 2](#fig2){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). Subsequently, the PE produced by [Psd1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005113) must be transported back to the ER to undergo methylation leading to PC. PS is transported into the mitochondria by an ubiquitin-regulated process that is insensitive to disruption of vesicular trafficking and involves specialized regions of apposition of mitochondria and ER known as the mitochondria-associated ER or MAM ([@bib66]; [@bib367]; [@bib366]; Achleitner *et al.* 1999; [@bib379]). An ER--mitochondria tethering complex potentially involved in movement of phospholipids between the ER and mitochondria has been described ([@bib211]).

The complex relationship between phospholipid metabolism in the ER and the synthesis and breakdown of cytosolic LD represents another example of the intricate interaction among cellular compartments that occurs in the course of lipid metabolism. LD are not merely storage depots for TAG and steryl esters. They are metabolically active; harboring multiple enzymes involved in lipid metabolism ([@bib10]; [@bib299]; [@bib122]; [@bib208]) (See also chapter: *Lipid Droplets and Peroxisomes*). Interaction of LD with the ER, mitochondria, and peroxisomes has been reported ([@bib122]). [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) clearly plays a critical role in TAG synthesis, LD formation, and the balance between nuclear/ER membrane proliferation and LD formation (Carman and Han 2009a; [@bib410]). Several enzymes involved in TAG synthesis show a dual localization to the ER and LD ([Figure 2](#fig2){ref-type="fig"}, [Table 1](#t1){ref-type="table"}), including acyl-DHAP reductase ([Ayr1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001386)), glycerol-3-P acyltransferase ([Gpt2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001775)), and acyl-CoA--dependent DAG acyltransferase ([Dga1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005771)). Formation of LD is believed to occur between the leaflets of the ER membrane, but alternative models such as vesicular trafficking have also been suggested ([@bib361]; [@bib93]; [@bib94]). The close interaction of LD with mitochondria and peroxisomes also underscores the important role of LD in metabolism ([@bib122]). TAG levels fluctuate drastically during cellular growth and division, and multiple conditions contribute to the level of TAG storage in LD in stationary phase cells ([@bib217]; [@bib70]; [@bib71]; [@bib299]; [@bib405]). As cells exit stationary phase, TAG hydrolysis supplies precursors for membrane lipid synthesis. As active cellular growth progresses, *de novo* FA synthesis increases, satisfying cellular requirements for lipid synthesis but even while TAG turnover is still in progress, *de novo* formation of TAG and LD is initiated ([@bib217]; [@bib405]). Methods for imaging-based screening of mutant libraries have been designed to identify factors involved in LD content, morphology, and mobilization ([@bib385]; [@bib386]) and screens using such methods have identified \>200 genes that potentially influence these processes ([@bib350]; [@bib95]). However, there is surprisingly little overlap between the mutants identified in the published screens, indicating that current screens are far from being saturated.

Roles of lipids in organelle function and morphology {#s8}
----------------------------------------------------

Due to the ubiquitous presence of most phospholipids in all subcellular membranes it can be difficult to assess specific phospholipid functions, in particular organelles. However, quite specific functions have been attributed to several lipids in the mitochondrion. For example, PE synthesized in the mitochondria by [Psd1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005113) plays an important role in stabilizing mitochondrial protein complexes ([@bib23]; [@bib271]). Consequently, the *[psd1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005113)* mutant is nonviable in conjunction with defects in components of the prohibitin complex, which functions as a protein and lipid scaffold and ensures the integrity and functionality of the mitochondrial inner membrane ([@bib272]; [@bib295]; [@bib374]; [@bib273]). In another example, CL, which is present only in the mitochondrion ([@bib229]), plays an important role in mitochondrial genome stabilization and higher order organization of components of the mitochondrial respiratory chain ([@bib213]; [@bib406]; [@bib408]; [@bib249]; [@bib187]). However, CL function reaches beyond the mitochondria, indirectly regulating morphology and acidification of the vacuole through the retrograde (*[RTG2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003221)*) signaling pathway and the *[NHX1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002864)*-encoded vacuolar Na^+^/H^+^ exchanger ([@bib54]). Lack of CL in *[crd1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002301)* mutants is in part compensated by an upregulation of the PE content, which is dependent on the mitochondrial synthesis through [Psd1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005113) ([@bib119]). Defects in [Crd1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002301) are also, in part, compensated by an increase in the precursor lipid PGP. Accordingly, mutation of the *[PGS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000510)* gene encoding PGP synthase leads to more pronounced mitochondrial defects and a petite negative phenotype ([@bib178]; [@bib48]).

Alterations in organelle morphology and/or function observed in response to changes in lipid composition due to mutation or pharmacological inhibition of enzymes ([@bib318]) provide tantalizing clues as to the roles of specific lipids. Notably, the *[pah1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)* mutant exhibits the expansion of the nuclear/ER membrane and up-regulation of phospholipid biosynthesis genes ([@bib314]). As discussed previously, dephosphorylation of PA by [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) provides DAG for the synthesis of TAG, as well as PE and PC in the Kennedy pathway. Consequently, the *[pah1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)* mutant has elevated PA levels, which result in up-regulation of phospholipid biosynthesis (see below) and membrane proliferation ([@bib145]; [@bib43]; [@bib39]). A number of mutants defective in FA metabolism also exhibit morphological abnormalities. For example, conditional mutants defective in FA desaturation (*[ole1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)/[mdm2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)*) show defective mitochondrial morphology and distribution upon cell division ([@bib344]). The finding that several dozen proteins species are required to sustain cell viability in the presence of unsaturated FA suggests an enormously complex network of processes and interactions to maintain membrane homeostasis and function ([@bib234]). In another example, a conditional *[acc1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005299)* mutant defective in FA *de novo* synthesis has impaired morphology of the vacuole due to reduced acylation of [Vac8](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000739) that is involved in stabilizing the vacuolar membrane and vacuole inheritance ([@bib320]). Mutants defective in FA elongation show similar fragmentation of the vacuole due to impaired synthesis of sphingolipids, which are important for the stability of the vacuolar ATPase complex ([@bib65]).

Due to their important roles in protein modification, myristic and palmitic acid affect the membrane association of numerous proteins and consequently influence signaling, membrane function and organelle morphology ([@bib78]). *[NMT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004185)* encodes the essential N-myristoyl transferase that attaches coenzyme A-activated myristic acid (C~14~-CoA) to a glycine residue close to the N-terminus of target proteins, resulting in cleavage of the peptide bond and *N*-terminal glycine acylation ([@bib365]). Although the myristoyl residue is shorter than the typical C~16~ or C~18~ chain length found in membrane phospholipids and, therefore may not fully interdigitate into a membrane leaflet, it serves an essential function in promoting membrane association of proteins ([@bib82]). Palmitoylation of internal cysteine residues within the peptide chain plays an important role in post-translational modification of some 50 proteins in yeast ([@bib312]), modulating membrane association, folding and activity. Protein palmitoylation is catalyzed by seven members of the "Asp-His-His-Cys-cystein-rich" (DHHC-CRD) domain family of proteins, and includes the [Erf2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004236)/[Shr5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005470) complex, [Akr1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002672), [Akr2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005560), [Pfa3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005270), [Pfa4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005363), [Pfa5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002867), and [Swf1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002533). Among the substrates for palmitoylation are [Vac8](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000739), SNAREs, and [Ras2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005042), indicating important regulatory functions for this FA modification of proteins in multiple pathways involved in membrane trafficking and signaling.

Mechanisms of compartmentalization and localization of enzymes of lipid metabolism {#s9}
----------------------------------------------------------------------------------

Many enzymes involved in glycerolipid metabolism have transmembrane domains ([Tables 1](#t1){ref-type="table"}--[3](#t3){ref-type="table"}), which anchor the proteins in their specific membrane environment and promote access to hydrophobic lipid substrates. However, several membrane-associated enzymes lack defined transmembrane spanning domains and membrane interaction is mediated, perhaps in a regulated manner, with specific membrane-resident anchor proteins. For example, *[PIK1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005211)*-encoded PI 4-kinase binds to the membrane through [Frq1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002781) and the *[VPS34](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004230)*-encoded PI 3-kinase binds through [Vps15](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000301) ([@bib347]). In addition, enzymes may bind to the membrane through specific interaction with lipids in the membrane, such as PI 3-P, PI 4-P, PI 3,5-P~2~ and PI 4,5-P~2~ through PH, PX, FYVE or ENTH domains ([@bib347]). A number of enzymes involved in lipid biosynthesis utilize water soluble lipid precursors, including the choline and ethanolamine kinases and the enzymes of the FAS complex, involved in long chain FA synthesis, and are localized to the cytosol. Acyl-CoA, generated by the FAS complex, has a highly amphiphilic structure and easily associates with membrane surfaces, facilitating the subsequent incorporation of the acyl chains into lipids by membrane-bound enzymes. However, [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is an example of an enzyme that is associated with both cytosolic and membrane compartments. PA, the substrate for [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775), is present in the membrane, but the largest pool of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is cytosolic, highly phosphorylated and inactive. [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) must be dephosphorylated by the [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007) complex in order to be functional *in vivo* ([@bib314]; [@bib141]; Carman and Han 2009a; [@bib61]). Dephosphorylation of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) by the [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007) complex leads to its membrane association and its activation (Choi *et al.* 2011), leading to the production of DAG and TAG and the lowering of PA levels, which in turn affects regulation of phospholipid biosynthetic genes (see below) ([@bib43]; [@bib39]).

Regulation of lipid metabolism in response to membrane function {#s10}
---------------------------------------------------------------

Several regulatory circuits have been uncovered that govern, by different mechanisms, the cross-talk between membrane function and lipid synthesis. Proteins involved in this regulation may sense specific changes in lipid composition, membrane charge, fluidity, or curvature. One such mechanism controls the expression of the fatty acid desaturase, [Ole1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023), by the ER membrane-bound transcription factors [Mga2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001472) and [Spt23](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001503), which are cleaved and released from the membrane in response to changes in membrane fluidity or permeability ([@bib164]). Both proteins are synthesized as larger, ER membrane-bound proteins that are ubiquitinated and cleaved by the activity of the 26S proteasome under low oxygen conditions, in conjunction with the ubiquitin-selective chaperone *[CDC48](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002284)^[UFD1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003280)/[NPL4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000374)^*. This cleavage detaches the soluble fragments from their membrane anchors, and allows them to enter the nucleus to control transcription of *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* and several other genes through the low oxygen response (LORE) promoter element. Proteasomal cleavage of [Mga2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001472) and [Spt23](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001503) requires the essential E3 ubiquitin ligase, [Rsp5](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000927), and lack of this activity results in a cellular requirement for unsaturated FA. Cleavage of [Spt23](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001503) and [Mga2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001472) in the ER is believed to be regulated by the membrane environment, adjusting membrane lipid composition through the control of FA desaturation. Under normoxic conditions, *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* expression is activated by the oxygen-responsive transcription factor [Hap1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004246). Addition of unsaturated FA, including linoleic acid (C~18:2~) or arachidonic acid (C~20:4~), which are normally not present in yeast, results in a drastic and rapid reduction of *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* mRNA expression and stability. However, low oxygen tension leads to a massive induction of *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* expression through the LORE element present in its promoter. This induction is believed to increase efficiency of FA desaturation to support cellular growth under oxygen limiting (hypoxic) conditions ([@bib240]; see also the chapter on Lipid Droplets and Peroxisomes for more discussion of fatty acid metabolism and regulation). [Mga2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001472) (but not [Spt23](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001503)) was also shown to be responsible for the rapid, but transient, up-regulation of *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* and other LORE-containing genes observed when inositol is added to cultures of wild-type yeast growing logarithmically in the absence of inositol ([@bib182]). Regulation of the phospholipid biosynthetic genes containing the UAS~INO~ promoter element also occurs in response to changes in the lipid composition in the ER membrane, through the binding of the [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) repressor to PA (see below). The ER is also the locus of complex regulatory cross-talk involving membrane expansion, the secretory pathway, the unfolded protein response (UPR) pathway, and phospholipid metabolism ([@bib69]; [@bib417]; [@bib25]; [@bib46], [@bib47]; [@bib171]; [@bib31]; [@bib182]; [@bib113]; [@bib322]).

Another example of regulation of lipid metabolism in yeast in response to changing membrane conditions was discovered in the course of analysis of a *[cho2Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389)[opi3Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834)* mutant strain completely defective in PC formation via the PE methylation pathway ([@bib28]). When this mutant is deprived of choline, PC levels decline and as this process progresses, concomitant changes in acyl-chain distribution occur in PC and other phospholipids, especially PE. However, similar changes were not observed in the neutral lipid fraction. The shortening and increased saturation of PE acyl chains decreases the bilayer forming potential of PE and [@bib28] suggest that phospholipid remodeling under these conditions may provide a mechanism for maintaining intrinsic membrane curvature. The nature of such a mechanism has not yet been defined, but yeast has a number of proteins harboring a BAR domain, including [Rvs161](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000602) and [Rvs167](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002796), which bind to liposomes in a curvature-dependent manner and promote tubule formation *in vitro. In vivo* studies in yeast indicate inappropriate regulation of phosphoinositide and sphingolipid metabolism impinges on Rsv161 and Rsv167 function ([@bib420]; [@bib401]). The [Rim101](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001019) pathway, which is involved in regulating cellular pH in response to alkaline conditions and cell wall biogenesis, also appears to be involved in sensing membrane curvature ([@bib241]).

Genetic Regulation of Glycerolipid Synthesis {#s11}
============================================

In wild-type cells, both glycerolipid composition and the expression of lipid biosynthetic genes are influenced by a wide variety of growth conditions, including growth phase, temperature, pH, and the availability of nutrients such as carbon, nitrogen, phosphate, zinc, and lipid precursors. Transcript levels of certain lipid biosynthetic genes in yeast are also regulated by message stability. A number of viable mutants defective in genes encoding lipid metabolic enzymes, transporters, and regulatory factors exhibit changes in lipid composition. These complex and interrelated topics have been the subjects of numerous reports and reviews ([@bib152]; [@bib41]; [@bib280]; [@bib153]; [@bib42]; [@bib109]; [@bib181]; [@bib314]; [@bib43]; [@bib52]; [@bib71]; [@bib112]; [@bib229]; [@bib285]; [@bib113]; [@bib323]; [@bib402]; [@bib40]), as discussed below with a focus on the transcriptional regulation of lipid biosynthetic genes in response to PA.

Regulation of transcript abundance by mRNA degradation {#s12}
------------------------------------------------------

The transcript abundance of some glycerolipid metabolic genes is regulated at the level of mRNA degradation. Genes that exhibit this level of regulation include *[CHO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000828)* ([@bib59]) and *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* ([@bib120]; [@bib377]; [@bib240]). In wild-type cells, *[CHO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000828)* mRNA is moderately stable with a half-life of 12 min when compared with other *S. cerevisiae* mRNAs that have half-lives ranging from 1 to 60 min ([@bib155]). However, *[CHO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000828)* mRNA is greatly stabilized with a half-life \>45 min in respiratory mutants ([@bib59]). This results in increased levels of the PS synthase protein and its associated activity ([@bib59]). Given that *[CHO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000828)* mRNA decays by the primary 5′--3′ decay pathway when cells are respiratory sufficient ([@bib284]), it is reasonable to predict that the rate of deadenylation and/or decapping may be reduced when respiration is blocked. The *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* transcript is destabilized when cells are supplemented with unsaturated FA ([@bib120]; [@bib377]; [@bib240]). This FA-regulated decay of *[OLE1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003023)* mRNA occurs through both the 5′--3′ general pathway and via exosomal 3′--5′ degradation activities ([@bib240]).

Transcriptional regulation by inositol and choline {#s13}
--------------------------------------------------

Expression of the *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* gene ([Figure 3](#fig3){ref-type="fig"}, [Table 2](#t2){ref-type="table"}) is repressed by ≥100-fold in the presence of inositol. Exogenous choline results in an additional severalfold reduction in *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* transcript level but only if inositol is also present. However, in the absence of exogenous inositol, choline has little or no effect on *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression (Hirsch and Henry 1986; [@bib158]; [@bib180]). Other genes encoding enzymes of lipid metabolism, including many involved in PC biosynthesis, show similar patterns of regulation in response to inositol and choline ([@bib41], [@bib42], [@bib43]; [@bib280]; Henry and Patton-Vogt 1998; Jesch and Henry 2005; [@bib180]; [@bib52]; [@bib40]). However, no other gene in the yeast genome shows as great a repression ratio in the presence of inositol and choline as *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* ([@bib313]; Jesch *et al.* 2005, [@bib182]).

The regulation ([Figure 3](#fig3){ref-type="fig"}) controlling the expression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* and coregulated genes of lipid metabolism has been the subject of a number of recent comprehensive reviews ([@bib43]; [@bib52]; [@bib40]). Expression of these genes is controlled by the *cis*-acting element, consensus 5′CATGTGAAT3′ ([@bib16]; [@bib123]), known as the inositol sensitive upstream activating element (UAS~INO~), or alternatively as the inositol/choline responsive element (ICRE) (Schuller *et al.* 1992). The [Ino2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002530)-[Ino4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005468) heterodimer, which is required for activation of transcription of UAS~INO~-containing genes, binds to this site (Ambroziak and Henry 1994). Genome-wide location analysis confirmed the sequence of the UAS~INO~ element and the binding of the [Ino2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002530)-[Ino4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005468) heterodimer to the element across the genome ([@bib224]; [@bib148]). Since both [Ino2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002530) and [Ino4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005468) are required for activation of expression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)*, *[ino2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002530)*, and *[ino4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005468)* mutants exhibit inositol auxotrophy (Ino^−^ phenotype). However, since many genes involved in lipid metabolism in addition to *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* contain the UAS~INO~ promoter element ([@bib123]), the *[ino2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002530)* and *[ino4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005468)* mutants exhibit altered phospholipid compositions including reduced PC content, even when growing in the presence of inositol ([@bib237]). The fact that the *[INO2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002530)* regulatory gene also contains a UAS~INO~ element in its promoter, and is auto-regulated in response to inositol, adds an additional layer of complexity to this regulatory mechanism ([@bib5], [@bib52]). The *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* locus has also recently been reported to localize at the nuclear periphery when it is being actively transcribed ([@bib31]), through a chromatin-mediated mechanism that persists for several generations following addition of inositol ([@bib30]).

Repression of UAS~INO~-containing genes in response to the presence of exogenous inositol involves the [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) repressor ([@bib158]; [@bib416]) ([Figure 3](#fig3){ref-type="fig"}), which interacts with transcriptional activation domains in [Ino2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002530) ([@bib79]). [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) has also been reported to interact with a number of other regulatory proteins ([@bib52]), including the pleiotropic corepressors, [Sin3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005364) and [Ssn6](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000316) (Jaschke *et al.* 2011). Deletion of the *[OPI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* gene renders the cell incapable of repressing UAS~INO~ genes in response to inositol, and leads to expression of UAS~INO~-containing genes at levels that exceed their normal derepressed levels by severalfold, whether inositol or choline are present or not ([@bib416]; [@bib313]; [@bib180]). Such high levels of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression lead to **o**ver-**p**roduction of **i**nositol (the Opi^−^ phenotype for which the *[opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* mutants are named) and the excess inositol excreted from Opi^−^ mutants can be detected in a plate assay ([@bib123],[@bib411]). In addition, even when growing in the absence of inositol, *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* cells have elevated levels of PI and levels of other lipids that resemble those of wild-type cells growing in the presence of inositol ([@bib203]).

Role of PA in regulation of UAS~INO~-containing genes {#s14}
-----------------------------------------------------

Opi^−^ phenotypes are also associated with mutants (*[cho1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000828)*, *[cho2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389)*, *and [opi3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834)*) defective in the synthesis of PC via the CDP-DAG pathway ([@bib125]; [@bib225]; [@bib349]; [@bib245]) ([Figure 2](#fig2){ref-type="fig"}). Similar to the *[opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* mutant, *[cho2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389)* and *[opi3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834)* mutants overexpress *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* and fail to repress *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* and other UAS~INO~-containing genes in response to inositol. However, in contrast to *[opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* mutants, the constitutive overexpression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* and Opi^−^ phenotypes of *[opi3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834)* and *[cho2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389)* mutants are suppressed when they are grown in the presence of exogenous soluble precursors that restore PC biosynthesis by entering the Kennedy pathway downstream of their respective genetic lesions in PE methylation ([Figure 2](#fig2){ref-type="fig"}). Thus, the Opi^−^ phenotype is eliminated and PC biosynthesis is restored in *[cho2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389)* mutants grown in the presence of monomethylethanolamine (MME), dimethylethanolamine (DME), or choline ([@bib349]), while these phenotypes are corrected only by DME and choline in *[opi3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834)* mutants ([@bib245]). Such observations led to the hypothesis that the mechanism by which the yeast cell senses the presence of exogenous inositol, choline, and other phospholipid precursors, such as serine, ethanolamine, MME, and DME, involves their effect on phospholipid synthesis ([@bib41]).

Further support for this hypothesis came from studies involving strains carrying temperature-sensitive mutations of the essential PI/PC transport protein, [Sec14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004684). While a full discussion of the biology of [Sec14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004684) is beyond the scope of this review article, the role it has played in discovery that PA is the signaling molecule controlling *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression will be covered in brief here. The growth and secretory phenotypes of *[sec14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004684)^ts^* mutants are suppressed by mutations in any one of the three genes encoding enzymes in the Kennedy pathway for PC biosynthesis (*i.e.*, *[cki1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004123)*, *[pct1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003434)*, and *[cpt1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005074)*) ([@bib67]). Such strains (for example: *[sec14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004684)^ts^[cki1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004123)*) have Opi^−^ phenotypes and excrete choline (Opc^−^ phenotype) ([@bib287]). These phenotypes are due to increased PA levels resulting from elevated turnover of PC, catalyzed by the *[SPO14](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001739)*-encoded phospholipase D ([@bib341]; [@bib392]). These observations led to the identification of PA as the probable signaling lipid responsible for derepression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* and coregulated genes in the absence of exogenous inositol ([@bib153]). This model is consistent with the Opi^−^ phenotypes of mutants defective in reactions in the CDP-DAG pathway for PC synthesis and the fact that these phenotypes are suppressed by supplying these mutants with precursor that enters the Kennedy pathway downstream of the defect in the CDP-DAG pathway ([@bib153]). Interruption of any of the reactions downstream of PA via the CDP-DAG pathway leads to a buildup of PA and overexpression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)*, which raises endogenous inositol production. This leads to excretion of inositol and renders the cell insensitive to exogenous inositol ([@bib153]). Metabolites that enter the Kennedy pathway downstream of the specific metabolic lesion counteract PA build up by increasing the use of DAG in the Kennedy pathway ([Figure 2](#fig2){ref-type="fig"}). Also consistent with this model is the Opi^−^ phenotype observed in cells engineered to have reduced expression of *[PIS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006317)*, thereby slowing PI synthesis and raising PA levels ([@bib176]).

The mechanism by which PA regulates *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression was elucidated when [@bib236] showed that [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) contains PA binding domains that facilitate its interaction with PA in the perinuclear ER in cells growing in the absence of inositol ([Figure 3](#fig3){ref-type="fig"}). [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) also contains a motif known as FFAT (two phenylalanines in an acidic tract) that binds to [Scs2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000922), an integral ER membrane protein ([@bib235]). To remain localized to the ER membrane in the absence of inositol, [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) must interact with both [Scs2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000922) and PA. In wild-type yeast cells, addition of inositol to the growth medium leads to a dramatic increase in the rate of synthesis of PI, resulting in consumption of both PA and CDP-DAG. As PA levels drop, [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) is released from the ER and enters the nucleus where it represses expression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* and other UAS~INO~-containing genes ([@bib236]). Consistant with this model, mutations in [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) that interfere with its interaction with either PA or [Scs2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000922) result in Ino^−^ phenotypes ([@bib236]) and *[scs2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000922)* mutants also exhibit an Ino^−^ phenotype (Nikawa *et al.* 1995). Increased PC synthesis via the Kennedy pathway is also characteristic of *[scs2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000922)* mutants, a phenotype that has not been fully explored, and mutations blocking PC synthesis by this route suppress both the Ino^−^ phenotype and increased synthesis of PC in the *[scs2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000922)* mutant ([@bib190]). Since, as described above, blocking the reuse of choline via the Kennedy pathway should reduce the draw on PA and thus enhance *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression, these phenotypes are consistent with the model of [@bib236] concerning [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) function ([Figure 3](#fig3){ref-type="fig"}).

Regulation of gene expression by zinc {#s15}
-------------------------------------

The expression of several phospholipid synthesis genes is also regulated in coordination with mechanisms that control zinc homeostasis ([Figure 3](#fig3){ref-type="fig"}) ([@bib36]; [@bib85]). Zinc is an essential nutrient required for the growth and metabolism of *S. cerevisiae* ([@bib85]). It is a cofactor for key metabolic enzymes and a structural component of a diverse set of proteins that include chaperons, lipid binding proteins, and transcription factors ([@bib373]; [@bib326]; [@bib88]; [@bib85]). Cells grown in medium lacking zinc exhibit the induced expression of plasma membrane and vacuolar membrane zinc transporters (encoded by *[ZRT1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003224)*, *[ZRT2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004120)*, *[ZRT3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001658)*, and *[FET4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004938)*) to maintain the cytosolic levels of zinc ([@bib131]; [@bib84], [@bib85]). At the same time, a reduction in zinc causes changes in membrane phospholipid composition that are brought about by changes in the expression of phospholipid synthesis enzyme activities ([@bib140], [@bib145]; [@bib172]; [@bib196]; [@bib36]). It is postulated that changes in phospholipid composition may govern the insertion, topology, and/or function of the membrane-associated zinc transporters ([@bib36]).

The regulation of phospholipid synthesis genes by zinc availability ([Figure 3](#fig3){ref-type="fig"}) involves the control of PA content through the activation of PI synthase function. This regulation occurs in the absence of inositol supplementation and is mediated by the zinc-sensing and zinc-inducible transcriptional activator [Zap1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003592) and the zinc-responsive *cis*-acting element (UAS~ZRE~) ([@bib36]). Zinc depletion causes an increase in the synthesis of PI through increased expression of PI synthase ([@bib172]; [@bib145]). This regulation is controlled by the interaction of [Zap1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003592) with a UAS~ZRE~ in the *[PIS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006317)* promoter ([@bib172]; [@bib145]). As discussed above, increased PI synthesis causes a decrease in PA content, which results in the [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)-mediated repression of UAS~INO~-containing genes and a decrease in the activities of the CDP-DAG pathway enzymes ([@bib172]). The major effects of zinc depletion on phospholipid composition include an increase in PI and a decrease in PE ([@bib172]). Although levels of enzymes in the CDP-DAG pathway are reduced by zinc depletion, the amount of PC is not significantly affected ([@bib172]). This is attributed to the [Zap1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003592)-mediated inductions of choline kinase and ethanolamine kinase for PC synthesis via the Kennedy pathway ([@bib196]; [@bib338]). Like *[PIS1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000006317)*, the *[CKI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004123)* and *[EKI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002554)* genes contain a UAS~ZRE~ in their promoters that interact with [Zap1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003592) for gene activation ([@bib196]; [@bib338]). [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)-mediated regulation of *[CKI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004123)* and *[EKI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002554)* are overcome by their derepression via [Zap1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003592) ([@bib196]; [@bib338]).

Among the genes in lipid metabolism that contain the UAS~ZRE~, *[DPP1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002692)* is the most highly regulated by zinc availability ([@bib238]; [@bib36]; [@bib85]). The *[DPP1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002692)* gene encodes DGPP phosphatase, an enzyme associated with the vacuole membrane ([@bib391]; [@bib363]; [@bib138]). This enzyme catalyzes the removal of the β-phosphate from DGPP, a minor phospholipid in yeast, to form PA, followed by the dephosphorylation of PA to form DAG ([@bib391]). The zinc-mediated regulation of *[DPP1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002692)* expression correlates with the metabolism of DGPP and PA in the vacuole membrane ([@bib140]). In zinc-replete medium, DGPP and PA account for 0.6 mol% and 1.4 mol% of the total phospholipids in vacuole membranes, but in zinc-depleted medium, the amounts of DGPP and PA are decreased to an undetectable level and 0.3 mol%, respectively ([@bib140]). The function of *[DPP1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002692)*-encoded DGPP phosphatase is still unclear. However, it is speculated that the enzyme controls the levels of DGPP and PA in vacuolar membranes, which in turn mediates the cellular functions occurring in response to zinc depletion ([@bib36]).

Regulation by phosphorylation {#s16}
-----------------------------

Phosphorylation is a major covalent post-translational modification by which the activity of an enzyme or a transcription factor is regulated ([@bib192]; [@bib34]; [@bib170]; [@bib189]; [@bib210]; [@bib233]). Global analyses of protein phosphorylation indicate that several enzymes and transporters of glycerolipid metabolism are subject to phosphorylation ([Tables 1](#t1){ref-type="table"}--[3](#t3){ref-type="table"}). Some proteins have many sites of phosphorylation, whereas others have only a few. It is also telling that many enzymes and transporters have no sites of phosphorylation, and thus the function of these proteins might be regulated by other mechanisms (*e.g.*, substrate availability). The identity of the protein kinases involved and the physiological consequences of their phosphorylations have only been determined for a few proteins in glycerolipid metabolism ([@bib40]). The protein kinases known to regulate the function of catalytic and regulatory proteins in glycerolipid metabolism include AMP-activated protein kinase, protein kinases A and C, casein kinase II, and cyclin-dependent kinase. Glycerolipid enzymes known to be *bona fide* substrates of protein kinases and regulated by phosphorylation include CTP synthetase, choline kinase, PS synthase, PA phosphatase, and TAG lipase. The repressor [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) is also regulated by phosphorylation. A discussion of these phosphorylations may be found in a recent review by [@bib40].

Regulation of PA phosphatase {#s17}
----------------------------

[Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is one of the most highly regulated enzymes in lipid metabolism. Its activity is governed by several of the biochemical mechanisms discussed above including phosphorylation, enzyme location, and modulation by components of lipid metabolism. As discussed above, the DAG generated in the [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) reaction is used for the synthesis of TAG ([@bib141]) and for the synthesis of PE and PC via the Kennedy pathway ([@bib35], 2008). The enzyme also plays a major role in controlling the cellular concentration of its substrate PA ([Figure 3](#fig3){ref-type="fig"}) ([@bib141]), the precursor of phospholipids that are synthesized via the CDP-DAG pathway ([@bib44]; [@bib42]; Carman and Han 2008). In addition, the substrate PA plays a signaling role (see above) in the transcriptional regulation of phospholipid synthesis genes ([@bib43]). *[pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)*Δ mutants exhibit a \>90% reduction in TAG content, as well as derepression of phospholipid synthesis genes and massive expansion of the nuclear/ER membrane ([@bib314]; [@bib142]). Thus, the regulation of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) activity governs the synthesis of TAG, the pathways by which phospholipids are synthesized, PA signaling, and the growth of the nuclear/ER membrane (Carman and Han 2008). [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is associated with the cytosolic and membrane fractions of the cell, and its association with the membrane is peripheral in nature ([@bib141]). Chromatin immunoprecipitation analysis indicates that [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) may also be localized in the nucleus ([@bib314]).

The association of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) with the membrane where its substrate PA resides is essential to its function *in vivo*, and membrane association is largely governed by the phosphorylation state of the enzyme ([@bib191]; [@bib61]). Phosphorylation favors a cytosolic association, whereas dephosphorylation favors a membrane association ([@bib61]). The important sites of phosphorylation that govern this regulation include the seven Ser/Thr-Pro targets for *[CDC28](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000364)*-encoded and *[PHO85](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005952)*-encoded cyclin-dependent kinases. [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is dephosphorylated by the [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007) phosphatase complex that is associated with the nuclear/ER membrane ([@bib334]; [@bib314]). In the absence of [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007), wild-type [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is enriched in the cytosol where it is physiologically inactive, whereas a nonphosphorylatable mutant of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) with alanine substitutions of [Cdc28](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000364) and [Pho85](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005952) target sites is enriched in the membrane and is physiologically active ([@bib61]). The requirement of [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007) indicates that [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is recruited to the membrane for its physiological function. Indeed, the [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007)--dependent membrane localization of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is enhanced by elevated levels of PA ([@bib191]). Once the enzyme is dephosphorylated, it anchors onto the nuclear/ER membrane via a short N-terminal amphipathic helix allowing for the production of DAG for TAG synthesis ([@bib191]).

Under normal physiological conditions (*i.e.*, presence of the [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007) complex), the level of wild-type [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) detected on the membrane is very low. In fact, microscopic analysis of live *S. cerevisiae* cells expressing [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)-GFP show a cytosolic localization without a detectable fluorescence signal associated with the nuclear/ER membrane unless PA levels are elevated ([@bib191]). Yet we know that [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) is physiologically active with respect to lipid metabolism throughout cell growth ([@bib141]). Purified [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) has a relatively high catalytic efficiency when compared with other enzymes of lipid metabolism ([@bib231]), and the lethal phenotype of cells that overexpress [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007) ([@bib314]) indicates that an excess of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) function is detrimental to cell physiology. Indeed, suppression of this phenotype by overexpression of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) ([@bib314]) led to the discovery of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) function ([@bib142]). Thus, under normal physiological conditions, the amount of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) associated with membranes must be small for its physiological function to be controlled, and this regulation must be mediated by the amount of the [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046)-[Spo7](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000000007) on the membrane. In support of this hypothesis, the expression level of [Nem1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001046) is 10-fold lower when compared with [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) ([@bib116]).

[Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) activity is also modulated by cytosolic- and membrane-associated factors. The nucleotides ATP and CTP, which are precursors for the synthesis of phospholipids ([@bib42]), are inhibitors of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) activity ([@bib388]). Indeed high levels of ATP favor elevated PA content and phospholipid synthesis, whereas low levels of ATP favor reduced PA content and an increase in the synthesis of TAG ([@bib388]). As discussed elsewhere, elevated CTP content favors an increase in PA content and derepression of UAS~INO~-containing phospholipid synthesis genes ([@bib275]). The patterns of regulation of PA phosphatase activity by ATP and by CTP are consistent with the regulation of lipid synthesis observed in cells that have fluctuations in ATP and CTP ([@bib388]; [@bib275]).

Membrane lipids modulate [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) activity. For example, CDP-DAG, PI, and CL enhance activity ([@bib389]), whereas the sphingoid bases phytosphingosine and sphinganine inhibit activity ([@bib390]). The major effect of the lipid activators is to decrease the *K*~m~ of [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) for PA. Sphinganine antagonizes the activation of PA phosphatase activity by CL and PI, whereas it causes an increase in the cooperativity of CL activation ([@bib389]). Conversely, sphinganine has little effect on the cooperativity of PI activation, but causes an increase in the activation constant for PI ([@bib389]). On the basis of the activation/inhibitor constants and cellular concentrations for these lipid effector molecules, their regulatory roles on [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) should be physiologically relevant ([@bib390]; [@bib389]).

DAG kinase counteracts PA phosphatase in regulating PA levels {#s18}
-------------------------------------------------------------

[Dgk1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005838) is a unique CTP-dependent nuclear/ER membrane-associated enzyme that catalyzes the formation of PA from DAG ([@bib143],[@bib144]). [Dgk1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005838) counteracts [Pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775) in controlling PA content and consequently, transcriptional regulation of UAS~INO~-containing genes ([@bib143],[@bib144]). *[DGK1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005838)* overexpression causes an increase in PA content, derepression of UAS~INO~-containing genes, and abnormal nuclear/ER membrane expansion ([@bib143]) like those that occur in the *[pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)*Δ mutant ([@bib314]; [@bib142]). Also consistent with the regulatory role of PA, *[DGK1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005838)* overexpression suppresses the inositol auxotrophy caused by *[PAH1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)* overexpression ([@bib143]), whereas the *[dgk1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005838)*Δ mutation suppresses the phenotypes caused by the *[pah1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004775)*Δ mutation ([@bib143],[@bib144]).

Ino^−^ and Opi^−^ phenotypes are associated with mutations affecting many functions {#s19}
-----------------------------------------------------------------------------------

To date, the Ino^−^ and Opi^−^ phenotypes of mutants affecting lipid metabolism, which have been examined in detail for correlation of changes in lipid metabolism with changes in *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression, have been consistent with predictions based on the role of PA as discussed above ([@bib43]). However, mutants defective in a wide variety of other cellular functions have also been reported to have these phenotypes ([@bib153]) and several genome-wide screens for mutants with Opi^−^ or Ino^−^ phenotypes have been conducted ([@bib146]; [@bib402]; Villa-Garciá *et al.* 2011).

The screen of the *Matα* viable yeast deletion collection conducted by [@bib146], using the Opi^−^ plate test, as well as an *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)*-LacZ reporter construct, identified 89 Opi^−^ mutants. Among these mutants were *[opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)*, *[cho2](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003389)*, *[opi3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003834)*, *[ume6](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002615)*, *[rpd3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005274)*, *[sin3](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000005364)*, and *[reg1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002435)*, which had previously been shown to affect *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression ([@bib153]; [@bib330]; [@bib276]; [@bib87]). [@bib146] also reported Opi^−^ phenotypes for the first time in mutants affecting functions such as the NuA4 histone acetyl transferase, vacuolar protein sorting, and other aspects of membrane trafficking and the UPR.

[@bib402] identified 231 mutants from the yeast haploid deletion collection that showed measurable growth reduction at 37°, when grown in medium lacking inositol. The major focus of this study was on the discovery of pH sensitive Ino^−^ phenotypes associated with mutants defective in all of the subunits of the vacuolar adenosine triphosphatase (V-ATPase) complex, as well as factors in the ER responsible for the assembly of this complex. The *[pma1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002976)-007* mutant, defective in the essential P-type ATPase of the plasma membrane, which regulates cellular pH, was also found to have an Ino^−^ phenotype, as was *[trk1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003665)*, defective in a K^+^ transporter that activates [Pma1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002976). The Ino^−^ phenotypes of these mutants were observed at pH 3 but were suppressed at pH 4 and 5 and this pH sensitivity was attributed to pH dependence of binding of [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) to PA. The binding of PA to [Spo20](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004619), a yeast SNARE ([@bib257]), was also shown to be pH sensitive, suggesting that binding of proteins to PA is affected by cellular pH. Changes in the ionization state of PA affect binding of [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) to PA *in vitro*, supporting the electrostatic/hydrogen bond switch model of [@bib212] for interaction of proteins with PA. Repression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* in response to glucose starvation also correlates to cellular pH, but not to PA levels. [@bib402] have concluded that the [Reg1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002435)-mediated mechanism that regulates *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression via the glucose response pathway ([@bib276]; [@bib330]) is most likely not dependent on the absolute level of PA, but rather on the effect of pH on the ionization state of PA.

The screen for Ino^−^ mutants of the diploid viable yeast deletion collection conducted by Villa-Garciá *et al.* (2011) has resulted in the identification of 419 genes, which when deleted confer the Ino^−^ phenotype under one or more growth conditions. This screen involves comparing growth in the presence and absence of inositol at two growth temperatures, 30° and 37°, in the presence and absence of choline. Choline sensitive Ino^−^ phenotypes and the strengthening of weak Ino^−^ phenotypes by choline are potentially attributable to reduction in PA levels due to the consumption of DAG produced from PA when PC is synthesized via the Kennedy pathway (see above) using exogenous choline ([@bib43]). Growth temperature has also been shown to influence lipid metabolism in wild-type and mutant strains. Growth at 37° results in an increased rate of synthesis of PI in wild-type cells growing in the presence of inositol ([@bib113]), as well as an increase in PC synthesis and turnover ([@bib81]). Among the gene ontology (GO) categories enriched among the Ino^−^ mutants identified by Villa-Garciá *et al.* (2011) are: response to stress, protein modification, chromosome organization, response to chemical stimulus, cellular carbohydrate metabolism, psuedohyphal growth, and transcription. Mutants in the category response to stress include a number with defects in stress response pathways that had previously been reported to be associated with Ino^−^ phenotypes, including the protein kinase C-cell wall integrity (PKC-CWI) ([@bib264]; [@bib183]), the UPR ([@bib69]; [@bib46]) and the glucose response pathway ([@bib331], [@bib332]). However, Ino^−^ phenotypes have also been observed in mutants affecting signaling pathways not previously reported to be associated with such phenotypes including: target of rapamycin (TOR), high osmolarity glycerol (HOG), cAMP-dependent protein kinase, calcineurin and filamentous growth and cell cycle regulation (Villa-Garciá *et al.* 2011).

Causes of Ino^−^ phenotypes {#s20}
---------------------------

It is often assumed that an Ino^−^ phenotype provides evidence that a mutant has impaired *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression or, alternatively, that a signaling pathway and/or a transcription factor defective in the mutant in question, is directly involved in regulating *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* transcription. For example, the Ino^−^ phenotypes of the *[ire1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001121)* and *[hac1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001863)* mutants, defective in UPR activation, have been attributed to a role for the [Hac1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001863) transcription factor in activating expression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* ([@bib69]). The evidence for this interpretation includes the observations that *[ire1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001121)* and *[hac1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001863)* mutants fail to sustain expression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* when shifted to medium lacking inositol and that the *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* mutation supresseses their Ino^−^ phenotypes ([@bib69]). [@bib69] also reported that growth in the absence of inositol activates the UPR in wild-type cells and that *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression is activated in wild-type cells treated with tunicamycin in the presence of normally repressing levels of inositol. However, activation of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression in response to tunicamycin in the presence of inositol was not observed by [@bib46] and *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* is repressed with normal kinetics in response to addition of inositol in cells in which the UPR was constitutively induced by constitutive expression of activated [Hac1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001863) ([@bib182]). The reasons for these divergent results with respect to the role of [Hac1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001863) in *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* transcription are not clear.

A number of mutants in the PKC-CWI pathway have Ino^−^ phenotypes that are intensified at 37° and in the presence of choline ([@bib264]; [@bib100]; [@bib183]; Villa-Garciá *et al.* 2011). Futhermore, the Ino^−^ phenotypes of these mutants are suppressed by *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)*. It is clear, however, that the PKC pathway has no direct role in regulating *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression. The PKC pathway mutant, *[slt2Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001072)/[mpk1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001072)*, exhibits normal *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* derepression in response to a shift to inositol medium even when choline is present at 37°, a condition under which growth ceases and the mutant begins to lose viability within 4--5 hr ([@bib264]). The *[stt4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004296)^ts^* and *[mss4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002616)^ts^* mutants, defective in the PI kinases that are responsible for producing the PI 4-P and PI 4,5-P~2~ pools on the plasma membrane and are essential for PKC-CWI signaling during heat stress ([@bib14]), also exhibit Ino^−^ phenotypes at semipermissive growth temperatures ([@bib183]). However, *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* undergoes normal derepression immediately following a shift to medium lacking inositol in the *[stt4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000004296)^ts^* and *[mss4](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000002616)^ts^* mutants, even at the temperature at which they exhibit an Ino^−^ phenotype ([@bib183]). Significantly, the PKC-CWI pathway is activated in wild-type cells grown in the absence of inositol ([@bib264]) in response to reduction in synthesis of inositol-containing sphingolipids ([@bib183]). Thus, it is clear that the Ino^−^ phenotypes of PKC-CWI mutants are not attributable to a defect in *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression, but rather to failure to mount a stress response that is essential for survival of stress caused by growth in the absence of inositol ([@bib264]; [@bib183]; Villa *et al.* 2011).

Supression of an Ino^−^ phenotype by *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* is also often cited as evidence that the mutant in question is defective in a functon that regulates *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)*. However, the *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* mutation also suppresses the Ino^−^ phenotypes of *[slt2Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001072)* and other PKC pathway mutants ([@bib264]), which, as discussed above, are not attributable to failure to express *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)*. The explanation for this observation lies in the fact that the *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* mutation does not simply restore *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* expression to the level seen in wild-type cells growing in the absence of inositol. Instead, the deletion of the *[OPI1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* gene completely eliminates the ability of the cell sense inositol, whether endogenously produced or exogenously supplied, leading expression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* at levels as high as 5- to 6-fold higher than normal derepressed levels (Bachhwat *et al.* 1995). As a consequence of the resulting overproduction of inositol, *[opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* cells have levels of PI and other lipids resembling the lipid composition of wild-type cells grown in the presence of high levels of exogenous inositol ([@bib203]). Indeed, *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* mutants excrete so much inositol that they support growth of any Ino^−^ mutant in their vicinity, the characteristic used in the original bioassay used in the isolation of Opi^−^ mutants (Greenberg *et al.* 1982a). Microarray experiments showed that, in contrast to wild-type cells, *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* cells do not exhibit activation of UPR target genes when grown in the absence of inositol ([@bib180]). This is presumably due to the fact that overexpression of the *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* gene in *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* cells produces sufficient inositol to repress expression of all genes that are normally activated in absence of inositol, except of course the UAS~INO~-containing genes, which are directly dependent on [Opi1p](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) for repression in the presence of inositol ([@bib180]). Thus, suppression by *[opi1Δ](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012)* of an Ino^−^ phenotype conferred by mutation of a given gene does not consitute sufficient evidence on its own that the gene product in question is involved in regulation of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)*.

Microarray studies have revealed that the transcript levels of hundreds of genes in yeast are affected by the availability of inositol and/or inositol plus choline in the medium ([@bib313]; [@bib180], [@bib182]; [@bib264]). Most of these "inositol-regulated" genes are not under the control of [Opi1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000001012) and/or involved in lipid metabolism and a number of these genes are known targets of the stress response pathways that are associated with Ino^−^ phenotypes, including the UPR and PKC pathways ([@bib180], 2006; [@bib264]; [@bib183]; Villa *et al.* 2011). As discussed above, expression of *[INO1](http://www.yeastgenome.org/cgi-bin/locus.fpl?dbid=S000003689)* at the level observed in wild-type cells growing in the absence of inositol does not suffice to support the rate of PI synthesis observed in the same cells growing in the presence of exogenous inositol ([@bib194]; [@bib412]). Moreover, in wild-type cells, the changes in lipid metabolism that occur in response to removal of inositol and/or its resupply have been shown to affect signaling associated with PA ([@bib236]; [@bib402]), and with inositol containing sphingolipids and the pools of PI 4-P and PI 4,5-P~2~ in the plasma membrane ([@bib183]).

As the exploration of the regulation and cell biology of lipid metabolism in yeast accelerates in response to genomic approaches, additional examples of lipid-mediated signaling influenced by the availability of lipid precursors are likely to be discovered. A major advantage of yeast in such studies is the fact, as described in this YeastBook chapter, that its lipid metabolism can readily be manipulated by changing the supply of exogenous precursors and/or by introducing mutations affecting specific steps in lipid metabolism.

Perspectives {#s21}
============

Monumental advancements have been made in determining gene enzyme relationships and elucidating the fundamental biochemistry, regulatory mechanisms, and cellular roles of lipids in the 20 years since the publication of the last edition of the *Molecular Biology of the Yeast Saccharomyces: Gene Expression* in 1992. Yet while the identities of many of the genes encoding enzymes, transporters, and regulatory factors controlling lipid metabolism in yeast have been discovered, described, and analyzed, there remain many gaps in our knowledge. The functions of many genes, genome-wide, have yet to be clarified and among them are certainly a considerable number of "missing links" in yeast lipid metabolism and its regulation. For example, the molecular organization of lipid biosynthetic pathways that ensures metabolic channeling of critical compounds, enzyme topology, and the integration of soluble and membrane-bound intermediates in these pathways is only beginning to be addressed. Furthermore, we do not have complete knowledge of the mechanisms by which lipids synthesized in one compartment are trafficked to other locations within the cell or the mechanisms by which the precise lipid compositions of specific membrane compartments are established and maintained. High-resolution lipidomic analyses that have uncovered some 100 different molecular species of glycero- and sphingolipids have added another level of complexity to this question. Moreover, our understanding of the regulatory networks that link lipid metabolism to other aspects of cell biology and metabolism, including energy metabolism, membrane biogenesis, and trafficking, signaling, and cell division, remains limited. However, the increasing availability of archived genetic and biochemical data on a wide variety of eukaryotic organisms and the extensive homologies that exist among eukaryotes are opening new avenues for pursuing these important challenges. Due to its genetic tractability and comparably "simple" lipid complement, yeast continues to be among the most attractive and important model systems for such research.
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